<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">cD98jXN4YHzX3xPJM4z8kLj</article-id>
      <article-id pub-id-type="other">00011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000300011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09600311</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000010</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Vacina&#231;&#227;o contra influenza e pneumococo na insufici&#234;ncia card&#237;aca: uma recomenda&#231;&#227;o pouco aplicada</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>Wolney de Andrade</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Margarete Domingues</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Oliveira</surname>
            <given-names>Lucia Brand&#227;o de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barros</surname>
            <given-names>Luciana da Silva Nogueira de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jorge</surname>
            <given-names>Ana Cristina da Silva Moreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Camila Mirante dos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Almeida</surname>
            <given-names>Daniella de Paiva</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cabral</surname>
            <given-names>Isa&#237;as Fiuza</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Souza</surname>
            <given-names>Renata Tavares de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Furquim</surname>
            <given-names>Thyago Ant&#244;nio Biagioni</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Teres&#243;polis</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Centro Universit&#225;rio Serra dos Org&#227;os</institution>
        <institution content-type="orgdiv1">Hospital das Cl&#237;nicas de Teres&#243;polis Costantino Ottaviano </institution>
        <institution content-type="orgdiv2">Cl&#237;nica de Insufici&#234;ncia Card&#237;aca</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>03</month>
        <year>2011</year>
      </pub-date>
      <volume>96</volume>
      <issue>3</issue>
      <fpage>240</fpage>
      <lpage>245</lpage>
      <history>
        <date date-type="accepted">
          <day>09</day>
          <month>08</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>25</day>
          <month>07</month>
          <year>2010</year>
        </date>
        <date date-type="received">
          <day>10</day>
          <month>01</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A insufici&#234;ncia card&#237;aca (IC) cursa com frequentes descompensa&#231;&#245;es e admiss&#245;es ao servi&#231;o de emerg&#234;ncia. Vacina&#231;&#227;o contra Influenza (INF) e Pneumococo (PNM) s&#227;o recomendadas nas diretrizes, entretanto, as infec&#231;&#245;es respirat&#243;rias s&#227;o a terceira causa de hospitaliza&#231;&#227;o na IC. OBJETIVO: Avaliar a frequ&#234;ncia da vacina&#231;&#227;o contra INF e PNM em pacientes com IC na rede p&#250;blica. M&#201;TODOS: Em estudo observacional realizado em Teres&#243;polis, regi&#227;o serrana fluminense, foram utilizadas tr&#234;s estrat&#233;gias: (I) estudo das requisi&#231;&#245;es para vacina contra INF e/ou PNM na Secretaria Municipal de Sa&#250;de, entre 2004 e 2006; (II) inqu&#233;rito direto a 61 pacientes com IC atendidos na aten&#231;&#227;o b&#225;sica sobre sua situa&#231;&#227;o vacinal contra INF e PNM; (III) inqu&#233;rito direto sobre situa&#231;&#227;o vacinal contra INF e PNM a 81 pacientes com IC cr&#244;nica descompensada atendidos na &#250;nica emerg&#234;ncia aberta &#224; rede p&#250;blica. RESULTADOS: Na estrat&#233;gia I, a vacina&#231;&#227;o contra INF e/ou PNM foi de 15,3% daqueles com indica&#231;&#245;es por doen&#231;as cardiovasculares e respirat&#243;rias. A mediana do tempo entre a indica&#231;&#227;o e a vacina&#231;&#227;o foi de 32 dias. Na estrat&#233;gia II, o percentual de vacinados contra INF, com idade &gt; 60 anos, foi de 23,1%, e de 24,6% contra PMN em todas as idades. Na estrat&#233;gia III, o percentual de pacientes vacinados contra INF foi de 35,8% e contra PNM foi de 2,5%. CONCLUS&#195;O: A taxa de vacina&#231;&#227;o contra INF e PNM em pacientes com IC &#233; muito baixa e ainda menor naqueles descompensados atendidos em servi&#231;o de emerg&#234;ncia.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Vacina&#231;&#227;o</kwd>
        <kwd>influenza humana</kwd>
        <kwd>pneumonia</kwd>
        <kwd>insufici&#234;ncia card&#237;aca</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>21</day>
        <month>01</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>Vacina&#231;&#227;o contra influenza e pneumococo na insufici&#234;ncia card&#237;aca - uma recomenda&#231;&#227;o pouco aplicada</p>
    <p>
      <bold>Wolney de Andrade Martins; Margarete Domingues Ribeiro; Lucia Brand&#227;o de Oliveira; Luciana da Silva Nogueira de Barros; Ana Cristina da Silva Moreira Jorge; Camila Mirante dos Santos; Daniella de Paiva Almeida; Isa&#237;as Fiuza Cabral; Renata Tavares de Souza; Thyago Ant&#244;nio Biagioni Furquim</bold>
    </p>
    <p> Cl&#237;nica de Insufici&#234;ncia Card&#237;aca (CLIC) do Hospital das Cl&#237;nicas de Teres&#243;polis Costantino Ottaviano (HCTCO) - Centro Universit&#225;rio Serra dos &#211;rg&#227;os (UNIFESO), Teres&#243;polis, RJ - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="nt">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A insufici&#234;ncia card&#237;aca (IC) cursa com frequentes descompensa&#231;&#245;es e admiss&#245;es ao servi&#231;o de emerg&#234;ncia. Vacina&#231;&#227;o contra Influenza (INF) e Pneumococo (PNM) s&#227;o recomendadas nas diretrizes, entretanto, as infec&#231;&#245;es respirat&#243;rias s&#227;o a terceira causa de hospitaliza&#231;&#227;o na IC. </p>
    <p><bold>OBJETIVO: </bold> Avaliar a frequ&#234;ncia da vacina&#231;&#227;o contra INF e PNM em pacientes com IC na rede p&#250;blica. </p>
    <p><bold>M&#201;TODOS:</bold> Em estudo observacional realizado em Teres&#243;polis, regi&#227;o serrana fluminense, foram utilizadas tr&#234;s estrat&#233;gias: (I) estudo das requisi&#231;&#245;es para vacina contra INF e/ou PNM na Secretaria Municipal de Sa&#250;de, entre 2004 e 2006; (II) inqu&#233;rito direto a 61 pacientes com IC atendidos na aten&#231;&#227;o b&#225;sica sobre sua situa&#231;&#227;o vacinal contra INF e PNM; (III) inqu&#233;rito direto sobre situa&#231;&#227;o vacinal contra INF e PNM a 81 pacientes com IC cr&#244;nica descompensada atendidos na &#250;nica emerg&#234;ncia aberta &#224; rede p&#250;blica. </p>
    <p><bold>RESULTADOS:</bold> Na estrat&#233;gia I, a vacina&#231;&#227;o contra INF e/ou PNM foi de 15,3% daqueles com indica&#231;&#245;es por doen&#231;as cardiovasculares e respirat&#243;rias. A mediana do tempo entre a indica&#231;&#227;o e a vacina&#231;&#227;o foi de 32 dias. Na estrat&#233;gia II, o percentual de vacinados contra INF, com idade &gt; 60 anos, foi de 23,1%, e de 24,6% contra PMN em todas as idades. Na estrat&#233;gia III, o percentual de pacientes vacinados contra INF foi de 35,8% e contra PNM foi de 2,5%. </p>
    <p><bold>CONCLUS&#195;O:</bold> A taxa de vacina&#231;&#227;o contra INF e PNM em pacientes com IC &#233; muito baixa e ainda menor naqueles descompensados atendidos em servi&#231;o de emerg&#234;ncia.</p>
    <p><bold>Palavras-chave:</bold> Vacina&#231;&#227;o, influenza humana, pneumonia, insufici&#234;ncia card&#237;aca.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A insufici&#234;ncia card&#237;aca (IC) &#233; uma s&#237;ndrome cl&#237;nica progressiva caracterizada pela fal&#234;ncia do m&#250;sculo card&#237;aco em bombear sangue suficiente para os sistemas org&#226;nicos. O crescimento dos fatores de risco cardiovascular e a maior longevidade da popula&#231;&#227;o contribuem para que a IC tenha car&#225;ter epid&#234;mico. A IC cursa com reinterna&#231;&#245;es frequentes e cada uma delas tem peso adicional na piora da curva de sobrevida. Dentre os principais fatores que precipitam as descompensa&#231;&#245;es e hospitaliza&#231;&#245;es, destacam-se a n&#227;o ades&#227;o ao tratamento, a isquemia mioc&#225;rdica aguda, a press&#227;o arterial elevada e as infec&#231;&#245;es respirat&#243;rias, como pneumonia e doen&#231;as virais<sup>1-2</sup>.</p>
    <p>A congest&#227;o pulmonar est&#225; presente em grande parte dos pacientes com IC e predisp&#245;e os mesmos &#224;s infec&#231;&#245;es respirat&#243;rias. Dentre elas, destaca-se a influenza pela alta preval&#234;ncia na comunidade, com a&#231;&#227;o direta e indireta na mortalidade e na hospitaliza&#231;&#227;o dos pacientes mais vulner&#225;veis &#224;s complica&#231;&#245;es virais, em especial, a popula&#231;&#227;o idosa. A vacina&#231;&#227;o contra influenza e contra pneumococo diminuiu a mortalidade global e cardiovascular em idosos, al&#233;m de ter reduzido o risco de hospitaliza&#231;&#245;es por pneumonia ou morte de todas as causas<sup>3-4</sup>. As evid&#234;ncias epidemiol&#243;gicas motivaram os programas de vacina&#231;&#227;o em popula&#231;&#245;es sob maior risco. As sociedades de especialistas em cardiologia na Am&#233;rica do Norte<sup>1</sup>, Europa<sup>5</sup> e Am&#233;rica Latina<sup>6</sup> inclu&#237;ram em suas diretrizes a recomenda&#231;&#227;o da vacina&#231;&#227;o contra influenza e a pneumonia pneumoc&#243;cica em cardiopatas cr&#244;nicos. No Brasil, tanto o Minist&#233;rio da Sa&#250;de<sup>7</sup> como a Sociedade Brasileira de Cardiologia<sup>2</sup> (SBC) tamb&#233;m recomendam as vacinas contra influenza e pneumococo para esses pacientes.</p>
    <p>Considerada a import&#226;ncia cl&#237;nica e epidemiol&#243;gica da IC, a relev&#226;ncia da vacina&#231;&#227;o como medida profil&#225;tica e a car&#234;ncia de dados sobre a efetividade da recomenda&#231;&#227;o da vacina&#231;&#227;o no Brasil, o presente trabalho teve por objetivo estimar a taxa de vacina&#231;&#227;o contra influenza e pneumococo em pacientes com IC sob acompanhamento ambulatorial e entre os descompensados, na rede p&#250;blica de Teres&#243;polis, regi&#227;o serrana fluminense.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>O estudo foi desenvolvido no munic&#237;pio de Teres&#243;polis, regi&#227;o serrana fluminense, com temperaturas m&#233;dias anuais abaixo da m&#233;dia nacional e com 150.268 habitantes no ano de 2007. O atendimento ambulatorial na rede p&#250;blica &#233; operado pela estrat&#233;gia de sa&#250;de da fam&#237;lia (ESF) em 29,5% e complementado pelas demais unidades b&#225;sicas (UBS) com total de cobertura de 35,3% da popula&#231;&#227;o. As unidades secund&#225;rias se articulam com a aten&#231;&#227;o b&#225;sica pelo sistema de refer&#234;ncia e contrarrefer&#234;ncia. A ESF &#233; administrada em cogest&#227;o entre o SUS e o Centro Universit&#225;rio Serra dos &#211;rg&#227;os (UNIFESO), institui&#231;&#227;o de ensino com 6 cursos de gradua&#231;&#227;o na &#225;rea da sa&#250;de, com efetiva inser&#231;&#227;o de docentes e discentes na referida rede. A maior unidade terci&#225;ria &#233; o hospital de ensino, de m&#233;dio porte, conveniado ao SUS, como &#250;nico servi&#231;o de urg&#234;ncia e emerg&#234;ncia aberto &#224; rede p&#250;blica da regi&#227;o &#224; &#233;poca do estudo. </p>
    <p>O estudo foi observacional, transversal e consistido por tr&#234;s estrat&#233;gias: </p>
    <p>
      <bold>Estrat&#233;gia I</bold>
    </p>
    <p>Estudo de todas as "<italic>Requisi&#231;&#245;es de Imunobiol&#243;gicos Especiais</italic>" na Secretaria Municipal de Sa&#250;de (SMS) de Teres&#243;polis, protocoladas no per&#237;odo entre jan/2004-dez/2006, com especial enfoque para as requisi&#231;&#245;es de vacina&#231;&#227;o contra influenza e/ou pneumococo com indica&#231;&#227;o por doen&#231;as cardiovasculares e respirat&#243;rias para adolescentes e adultos, considerados como aqueles maiores de 12 anos de idade. Considerou-se indica&#231;&#227;o cl&#237;nica por IC todas as indica&#231;&#245;es feitas na ficha de requisi&#231;&#227;o listadas a seguir: "insufici&#234;ncia card&#237;aca", "cardiomiopatia", "miocardiopatia", "cardiopatias isqu&#234;mica, alco&#243;lica, hipertensiva, reum&#225;tica, valvar, periparto ou outra etiologia espec&#237;fica". Em um &#250;nico caso n&#227;o se conseguiu determinar a indica&#231;&#227;o. </p>
    <p>A vacina&#231;&#227;o contra influenza e pneumococo em grupos especiais, por indica&#231;&#227;o cl&#237;nica, acontece atrav&#233;s de refer&#234;ncia e agendamento em &#250;nica unidade central. N&#227;o h&#225; vacina&#231;&#227;o contra pneumococo em unidades de ESF ou UBS nem em unidades secund&#225;rias ou campanhas nesse munic&#237;pio. A vacina&#231;&#227;o contra pneumococo &#233; exclusiva aos grupos com indica&#231;&#227;o cl&#237;nica, composto de v&#225;rias entidades e situa&#231;&#245;es. Portanto, n&#227;o h&#225; indica&#231;&#227;o de vacina&#231;&#227;o baseada em faixa et&#225;ria.</p>
    <p>
      <bold>Estrat&#233;gia II</bold>
    </p>
    <p>Inqu&#233;rito direto a 61 pacientes com diagn&#243;stico atribu&#237;do de IC, atendidos em ESF, UBS ou unidades secund&#225;rias sobre sua situa&#231;&#227;o vacinal contra influenza no ano anterior &#224; entrevista e contra pneumococo nos 5 anos anteriores &#224; entrevista. Os pacientes foram admitidos ao protocolo por ordem aleat&#243;ria de chegada &#224;s unidades e apresentaram m&#233;dia de idade de 66,5 &#177; 11,8 anos, com 52,0% do sexo feminino. De modo aleat&#243;rio, 8 unidades de ESF, uma UBS e uma unidade secund&#225;ria foram cobertas na amostragem. Respeitou-se a proporcionalidade de amostragem entre unidades urbanas (seis) e rurais (tr&#234;s) referente &#224; distribui&#231;&#227;o da popula&#231;&#227;o. Para fins de c&#225;lculo amostral, trabalhou-se com a preval&#234;ncia n&#227;o ajustada de IC de 2,0%. A amostra estudada representou 2,0% do total esperado de pacientes com IC no munic&#237;pio.</p>
    <p>
      <bold>Estrat&#233;gia III</bold>
    </p>
    <p>Inqu&#233;rito direto a 81 pacientes com diagn&#243;stico atribu&#237;do de IC cr&#244;nica agudizada atendidos no servi&#231;o de emerg&#234;ncia sobre sua situa&#231;&#227;o vacinal contra influenza, no ano anterior &#224; entrevista, e contra pneumococo, nos 5 anos anteriores &#224; entrevista. Todos os pacientes encontraram-se descompensados e foram inclu&#237;dos independentemente das etiologias, n&#237;veis de gravidade, causas de descompensa&#231;&#227;o ou outros crit&#233;rios. A ordem de admiss&#227;o ao protocolo foi aleat&#243;ria pela data do atendimento, com coleta direta dos dados, nos plant&#245;es cobertos pelos pesquisadores. Na impossibilidade do paciente fornecer a informa&#231;&#227;o pela gravidade de seu quadro cl&#237;nico, utilizaram-se dados fornecidos pelo familiar ou acompanhante. Foram exclu&#237;dos os pacientes com IC aguda ("de novo"), como aqueles com s&#237;ndromes coronarianas agudas ou miocardite, pois n&#227;o teriam tido o diagn&#243;stico e a oportunidade pr&#233;vios para vacina&#231;&#227;o. A coleta dos dados deu-se entre abr/2007-nov/2008. Os pacientes tiveram desfechos variados, como alta para acompanhamento ambulatorial, interna&#231;&#227;o ou &#243;bito. A m&#233;dia de idade do grupo foi de 63,6 &#177; 14,0 anos, sendo 52,0% do sexo masculino. Esse era o &#250;nico servi&#231;o de emerg&#234;ncia aberto &#224; rede p&#250;blica no munic&#237;pio &#224; &#233;poca da coleta dos dados e a amostra coletada de pacientes descompensados representou 2,7% da estimativa de preval&#234;ncia geral de IC n&#227;o ajustada no munic&#237;pio, para todas as classes funcionais.</p>
    <p>Os dados foram coletados ap&#243;s capacita&#231;&#227;o dos entrevistadores e treinamento em estudo-piloto. Question&#225;rio estruturado foi utilizado e, posteriormente, transferido para planilha eletr&#244;nica. Os resultados foram apresentados em valores absolutos e percentuais. A compara&#231;&#227;o da distribui&#231;&#227;o das propor&#231;&#245;es entre os grupos foi feita atrav&#233;s do teste qui-quadrado. O n&#237;vel de signific&#226;ncia adotado foi de 5,0%. </p>
    <p>O estudo teve aprova&#231;&#227;o na Comiss&#227;o de &#201;tica em Pesquisa do UNIFESO, sob o n&#250;mero 060 e 061/2006, assim como a aprova&#231;&#227;o na Secretaria Municipal de Sa&#250;de de Teres&#243;polis. Todos os pacientes das estrat&#233;gias II e III firmaram termo de consentimento ap&#243;s esclarecimento. Este projeto teve apoio do Programa de Inicia&#231;&#227;o Cient&#237;fica, Pesquisa e Extens&#227;o (PICPE-UNIFESO) e da Funda&#231;&#227;o Carlos Chagas Filho de Amparo &#224; Pesquisa do Estado do Rio de Janeiro (FAPERJ).</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>
      <bold>Estrat&#233;gia I</bold>
    </p>
    <p>No tri&#234;nio analisado, houve um total de 735 vacina&#231;&#245;es contra pneumococo em todo o munic&#237;pio de Teres&#243;polis, com predom&#237;nio da popula&#231;&#227;o pedi&#225;trica com 418 (56,9%), seguida das vacina&#231;&#245;es nos pacientes com idade <underline>&gt;</underline> 12 anos por todas as demais indica&#231;&#245;es cl&#237;nicas que n&#227;o cardiovascular ou respirat&#243;ria com 168 (22,9%). Por &#250;ltimo, aqueles por indica&#231;&#227;o cardiovascular ou respirat&#243;ria com idade <underline>&gt;</underline> 12 anos com 149 (20,3%). No per&#237;odo analisado, houve 184 refer&#234;ncias de vacina&#231;&#227;o contra influenza e/ou pneumococo &#224; Unidade Central, das quais foram 131 doses contra pneumococo, 35 contra influenza e 18 contra ambas. A mediana do tempo entre a indica&#231;&#227;o da vacina pelo m&#233;dico assistente e a data da vacina&#231;&#227;o foi de 32 dias, com intervalo de 1 a 377 dias. Demais caracter&#237;sticas dos vacinados contra INF e/ou PNM encontram-se dispostas na <xref ref-type="table" rid="tab01">Tabela 1</xref>.</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-96-03-0240-00010-gt01.jpg"/></table-wrap>
    <p>Dos vacinados contra INF e/ou PNM na unidade central, 183 pacientes tiveram as indica&#231;&#245;es analisadas e a vacina&#231;&#227;o por indica&#231;&#227;o cl&#237;nica de IC aconteceu em 15,3% dos referenciados por doen&#231;as cardiovasculares ou respirat&#243;rias. A principal indica&#231;&#227;o foi "<italic>pneumonias de repeti&#231;&#227;o</italic>" em pacientes pneumopatas (ver <xref ref-type="table" rid="tab02">Tabelas 2</xref>).</p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-96-03-0240-00010-gt02.jpg"/></table-wrap>
    <p>
      <bold>Estrat&#233;gia II</bold>
    </p>
    <p>Dos 61 pacientes avaliados nas unidades prim&#225;rias e secund&#225;rias, o percentual de pacientes com IC vacinados contra influenza foi de 72,1% contra 24,6% que negaram ter recebido a mesma, e ainda 3,3% que desconheciam. Quando tomados em separado aqueles com idade menor que 60 anos, obteve-se 23,1% de vacinados contra influenza em rela&#231;&#227;o ao total de pacientes nesta faixa et&#225;ria. Com rela&#231;&#227;o &#224; vacina&#231;&#227;o contra pneumococo, o percentual de pacientes que disseram ter tomado a vacina foi de 24,6%, contra 57,4% que negaram e 18,0% que desconheciam.</p>
    <p>
      <bold>Estrat&#233;gia III</bold>
    </p>
    <p>Dos 81 pacientes com IC descompensada atendidos no servi&#231;o de emerg&#234;ncia, o percentual de pacientes vacinados contra influenza foi de 35,8%, contra 64,2% que negaram ter recebido a mesma. O percentual de pacientes que afirmaram ter recebido a vacina pneumoc&#243;cica, nos &#250;ltimos 5 anos, foi de 2,5%, enquanto 62,9% negaram ter recebido a mesma e 34,6% desconheciam a vacina.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A incid&#234;ncia de IC nos EUA &#233; de aproximadamente 1.000 por 100.000 habitantes ap&#243;s os 65 anos de idade, dos quais 75,0% dos casos t&#234;m a hipertens&#227;o arterial sist&#234;mica como a prov&#225;vel etiologia<sup>1</sup>. A preval&#234;ncia de IC aumenta linearmente com a idade em ambos os sexos e a gravidade &#233; maior nos extremos de faixa et&#225;ria<sup>6</sup>. No Canad&#225;, chega a atingir 350.000, enquanto nos EUA aproximadamente 5 milh&#245;es de pessoas t&#234;m IC. Na Su&#233;cia, a estimativa &#233; de que atinja 2,0% da popula&#231;&#227;o<sup>8,9</sup>. No Brasil, a preval&#234;ncia de IC &#233; incerta, por&#233;m, est&#225; em ascens&#227;o devido &#224; maior sobrevida da popula&#231;&#227;o geral e &#224; maior efetividade dos medicamentos para prolongamento da vida dos pacientes com IC. Por estas raz&#245;es, a IC representa a principal causa de interna&#231;&#227;o no Sistema &#218;nico de Sa&#250;de (SUS) nos pacientes acima de 65 anos de idade<sup>8</sup>.</p>
    <p>Nas &#250;ltimas duas d&#233;cadas, no Brasil, ocorreu aumento progressivo das taxas de mortalidade hospitalar por IC com revers&#227;o nos &#250;ltimos anos<sup>2</sup>. As hospitaliza&#231;&#245;es contribuem para o custo total anual de 33,7 bilh&#245;es de d&#243;lares na economia americana, e no Brasil, no ano de 2002, o custo por paciente internado com IC foi estimado em R$ 4.033,62<sup>1,8</sup>. A maior parte do custo financeiro dos pacientes com IC deve-se &#224;s interna&#231;&#245;es frequentes. A rela&#231;&#227;o causal entre infec&#231;&#227;o respirat&#243;ria e descompensa&#231;&#227;o cl&#237;nica tem sido comprovada em diversos estudos epidemiol&#243;gicos. A vacina&#231;&#227;o contra infec&#231;&#245;es respirat&#243;rias tem efic&#225;cia na rela&#231;&#227;o custo-benef&#237;cio como medida de sa&#250;de p&#250;blica. Observou-se maior n&#250;mero de admiss&#245;es hospitalares por IC durante per&#237;odos de epidemia de influenza<sup>4,9-11</sup>. </p>
    <p>Al&#233;m disso, em ambiente nosocomial, os pacientes com IC t&#234;m risco aumentado de infec&#231;&#245;es pulmonares, em especial a pneumonia<sup>12</sup>. N&#227;o houve avalia&#231;&#227;o de custo-efetividade da vacina&#231;&#227;o contra influenza e pneumococo em pacientes com IC no Brasil nas bases consultadas. Entretanto, &#233; plaus&#237;vel inferir que a estrat&#233;gia de vacina&#231;&#227;o seja muito favor&#225;vel, at&#233; porque outras medidas com maior custo financeiro, como o fornecimento de medica&#231;&#227;o gratuita aos pacientes ambulatoriais, j&#225; foram estudadas com conclus&#227;o favor&#225;vel<sup>8</sup>.</p>
    <p>Ao analisarem-se os resultados das fichas de refer&#234;ncia para vacina&#231;&#227;o na Secretaria Municipal de Sa&#250;de (SMS), observou-se o irrelevante n&#250;mero de vacinados frente &#224; magnitude da preval&#234;ncia da IC. O munic&#237;pio de Teres&#243;polis teve cobertura vacinal para influenza, na popula&#231;&#227;o-alvo de idosos, de 84,6% em 2004, 97,5% em 2005 e 117,2% em 2006<sup>13</sup>. </p>
    <p>Deste modo, pode-se considerar que a baixa taxa de vacina&#231;&#227;o nos pacientes com IC encontrada neste trabalho n&#227;o foi advinda da inexist&#234;ncia de condi&#231;&#245;es estruturais que viabilizassem a vacina&#231;&#227;o contra influenza e pneumococo. As causas da baixa taxa de vacina&#231;&#227;o podem ser discutidas sobre tr&#234;s eixos: 1) a pouca indica&#231;&#227;o pelo profissional da sa&#250;de; 2) as dificuldades de acesso &#224; vacina e a complexidade do processo de vacina&#231;&#227;o; e 3) as causas dependentes do paciente. </p>
    <p>A inclus&#227;o da vacina&#231;&#227;o em cardiopatas cr&#244;nicos n&#227;o est&#225; incorporada na pr&#225;tica dos planos de cuidados das unidades da aten&#231;&#227;o b&#225;sica e especializada. Tal afirma&#231;&#227;o &#233; fundamentada na baixa taxa de vacina&#231;&#227;o contra influenza - vacina dispon&#237;vel uma vez ao ano nas pr&#243;prias unidades b&#225;sicas - entre aqueles com idade menor que 60 anos, ou seja, fora da indica&#231;&#227;o habitual. Neste trabalho, observou-se o predom&#237;nio de indica&#231;&#245;es para vacina&#231;&#227;o contra pneumococo por parte dos pediatras. Entre as indica&#231;&#245;es por doen&#231;as cardiovasculares e respirat&#243;rias em adolescentes e adultos, houve predom&#237;nio da indica&#231;&#227;o pelos pneumologistas em rela&#231;&#227;o aos cardiologistas e generalistas que atendem pacientes com IC.</p>
    <p>&#201; prov&#225;vel que a recomenda&#231;&#227;o de vacina&#231;&#227;o por indica&#231;&#227;o cl&#237;nica esteja mais incorporada &#224; pr&#225;tica cl&#237;nica dos pediatras e pneumologistas que dos cardiologistas e generalistas. As causas da n&#227;o prescri&#231;&#227;o das vacinas pelos m&#233;dicos assistentes n&#227;o foram objeto deste trabalho, entretanto, &#233; poss&#237;vel que advenham da falta de informa&#231;&#227;o acerca da indica&#231;&#227;o das vacinas aos pacientes com IC e da disponibilidade das mesmas na rede p&#250;blica. </p>
    <p>Houve predom&#237;nio de pacientes femininos e quase totalidade de resid&#234;ncia urbana dentre os vacinados contra pneumococo. Tais caracter&#237;sticas demogr&#225;ficas apontam para a prov&#225;vel influ&#234;ncia do acesso &#224; vacina como facilitador do processo de vacina&#231;&#227;o. O tempo mediano entre a indica&#231;&#227;o da vacina pelo m&#233;dico assistente e a efetiva&#231;&#227;o da vacina&#231;&#227;o tamb&#233;m foi demasiado longo nesta casu&#237;stica. O fato da vacina n&#227;o ser aplicada no mesmo dia em que &#233; solicitada resulta em obst&#225;culos, como custo de transporte, limita&#231;&#227;o de deslocamento pela dispneia de esfor&#231;o, disponibilidade de acompanhante e memoriza&#231;&#227;o das datas de agendamento. O preconceito dos idosos contra a vacina&#231;&#227;o, atribu&#237;do ao mito dos poss&#237;veis efeitos adversos, tamb&#233;m corrobora para a baixa ader&#234;ncia. Apesar das altera&#231;&#245;es imunol&#243;gicas descritas na IC, como aumento das interleucinas e do fator de necrose tumoral e a hiper-reatividade linfocit&#225;ria, a resposta imunol&#243;gica &#224; vacina&#231;&#227;o pneumoc&#243;cica &#233; eficaz, com produ&#231;&#227;o de anticorpos contra todos os sorotipos testados<sup>12</sup>.</p>
    <p>A amostra observada na aten&#231;&#227;o prim&#225;ria apresentou a m&#233;dia de idade esperada para a s&#237;ndrome na maioria dos estudos cl&#237;nicos, com discreto predom&#237;nio do sexo feminino, o que pode ser explicado pelo maior acesso das mulheres &#224;s unidades da aten&#231;&#227;o b&#225;sica<sup>8</sup>. A maior taxa de vacina&#231;&#227;o contra influenza deveu-se, seguramente, &#224; <italic>Campanha Nacional de Vacina&#231;&#227;o do Idoso</italic>, posto que, ao se separar por faixas et&#225;rias, v&#234;-se o predom&#237;nio dos vacinados entre os maiores de 60 anos, ponto de corte da indica&#231;&#227;o rotineira da vacina contra influenza. </p>
    <p>A disponibilidade da vacina contra influenza anualmente nas UBS e ESF s&#227;o facilitadores da vacina&#231;&#227;o. Entretanto, ainda h&#225; significativo percentual de n&#227;o vacinados, o que se explica pela falta de conhecimento da indica&#231;&#227;o cl&#237;nica e da seguran&#231;a da vacina nos pacientes com IC entre os profissionais da sa&#250;de. </p>
    <p>Singleton e cols.<sup>14</sup> observaram que a cobertura vacinal de influenza entre pacientes com doen&#231;a card&#237;aca est&#225; diretamente associada &#224; idade, pois encontraram 76,7% de indiv&#237;duos vacinados acima dos 65 anos, 49,2% entre 50 e 64 anos e, apenas, 22,7% vacinados com idade entre 18 e 49 anos. Hak e cols.<sup>15</sup> e Bittner e cols.<sup>16</sup> tamb&#233;m relataram resultados semelhantes quando pacientes com 65 anos ou mais, com condi&#231;&#245;es cl&#237;nicas de alto risco, tiveram uma maior taxa de vacina&#231;&#227;o em rela&#231;&#227;o aos de menor faixa et&#225;ria. Em estudo nacional realizado na Espanha, corroborou-se a necessidade de pol&#237;ticas de vacina&#231;&#227;o naqueles em faixas et&#225;rias menores, posto que frequentemente s&#227;o preteridos<sup>17</sup>. Bittner e cols.<sup>16</sup> alertaram que mesmo com as recomenda&#231;&#245;es da <italic>Organiza&#231;&#227;o Mundial da Sa&#250;de</italic> e do <italic>Centers of Disease Control and Prevention (CDC) </italic>para vacina&#231;&#227;o contra influenza em pacientes com doen&#231;as cardiovasculares, a cobertura encontra-se aqu&#233;m do esperado, mesmo nos pa&#237;ses desenvolvidos, uma vez que apenas 34,0% dos pacientes norte-americanos com doen&#231;a cardiovascular foram vacinados em 2005.</p>
    <p>Ao avaliar a cobertura vacinal contra pneumococo na aten&#231;&#227;o b&#225;sica, os dados tornam-se ainda mais alarmantes e os estudos mais escassos. Bratzeler e cols.<sup>3</sup> afirmaram que 54,1% de toda a popula&#231;&#227;o norte-americana acima de 65 anos nunca receberam essa vacina. No presente estudo, observou-se que, nas ESF e UBS, o percentual de pacientes com IC que negaram ter recebido a vacina pneumoc&#243;cica foi muito inferior &#224; vacina contra influenza e aos dados da literatura.</p>
    <p>O n&#250;mero apresentado de 81 pacientes com IC cr&#244;nica agudizada foi considerado significativo em rela&#231;&#227;o &#224; previs&#227;o do n&#250;mero total de pacientes com IC descompensada no munic&#237;pio e representou 2,7% do n&#250;mero total de pacientes com IC n&#227;o ajustado. Os pacientes com IC descompensada podem ser divididos em IC "<italic>de novo" </italic>ou<italic> aguda</italic> - geralmente secund&#225;rios &#224;s s&#237;ndromes coronarianas agudas ou o "cr&#244;nico agudizado". Esse &#250;ltimo foi objeto do presente estudo, geralmente portador de cardiomiopatia das diversas etiologias. Aqueles com IC <italic>de novo</italic> n&#227;o tiveram oportunidades do diagn&#243;stico e da vacina&#231;&#227;o pr&#233;via. Os pacientes descompensados constituem, em regra, aqueles nos est&#225;gios C e D do <italic>American College os Cardiologists/American Heart Association </italic>e classe funcional pr&#233;via III e IV da <italic>New York Heart Association</italic>, ou seja, subgrupo ainda mais restrito. </p>
    <p>No Servi&#231;o de Emerg&#234;ncia, houve predom&#237;nio de pacientes masculinos, o que reflete a distribui&#231;&#227;o da s&#237;ndrome de IC. Em 2007, a IC foi respons&#225;vel por 2,6% das hospitaliza&#231;&#245;es e 6,0% dos &#243;bitos registrados pelo SUS no Brasil, tendo consumido 3,0% dos recursos utilizados para atender todas as interna&#231;&#245;es realizadas pelo sistema<sup>2</sup>. Os dados sobre interna&#231;&#227;o por IC dispon&#237;veis no Brasil s&#227;o advindos das impress&#245;es diagn&#243;sticas levantadas &#224; &#233;poca da interna&#231;&#227;o e registradas na autoriza&#231;&#227;o para interna&#231;&#227;o hospitalar (AIH). Esse registro &#233; sabidamente pouco preciso pela heterogeneidade das nomenclaturas dos diagn&#243;sticos afeitos &#224; IC, comorbidades e outros diagn&#243;sticos presentes e quest&#245;es conjunturais do sistema de fatura das interna&#231;&#245;es. </p>
    <p>As taxas de vacina&#231;&#227;o entre os pacientes admitidos descompensados s&#227;o menores que aqueles da aten&#231;&#227;o b&#225;sica. &#201; poss&#237;vel inferir que o evento da descompensa&#231;&#227;o nesse grupo relacione-se com a menor taxa de vacina&#231;&#227;o e na menor ader&#234;ncia geral &#224; terap&#234;utica. As infec&#231;&#245;es respirat&#243;rias est&#227;o entre as causas mais comuns de descompensa&#231;&#227;o em diversas s&#233;ries. Em nossa institui&#231;&#227;o, as descompensa&#231;&#245;es por infec&#231;&#245;es respirat&#243;rias ganham o segundo lugar, ap&#243;s a transgress&#227;o da restri&#231;&#227;o hidrossalina e medicamentosa, provavelmente pela maior amplitude t&#233;rmica na regi&#227;o serrana fluminense, especialmente nos meses do inverno<sup>18</sup>. O momento da interna&#231;&#227;o hospitalar seria prop&#237;cio &#224; vacina&#231;&#227;o, entretanto, Bratzer e cols.<sup>3</sup> demonstraram que tal pr&#225;tica n&#227;o &#233; comum.</p>
    <p>Os benef&#237;cios da vacina&#231;&#227;o contra influenza e pneumococo n&#227;o se restringem &#224; preven&#231;&#227;o da descompensa&#231;&#227;o da IC por infec&#231;&#245;es respirat&#243;rias. A vacina&#231;&#227;o tem sido relacionada a outros ganhos, tais como a diminui&#231;&#227;o de eventos coron&#225;rios, tanto na preven&#231;&#227;o prim&#225;ria como na secund&#225;ria; redu&#231;&#227;o dos acidentes cerebrovasculares; decr&#233;scimo nas interna&#231;&#245;es e custos por outras doen&#231;as, principalmente entre os idosos<sup>15,19,20</sup>. Especula-se o impacto entre a vacina&#231;&#227;o contra influenza e a redu&#231;&#227;o de mortalidade por doen&#231;a isqu&#234;mica do cora&#231;&#227;o<sup>21,22</sup>. A vacina&#231;&#227;o traz benef&#237;cios nos desfechos de mortalidade e morbidade para todas as faixas et&#225;rias com condi&#231;&#245;es cl&#237;nicas de risco e se acentua nos mais idosos<sup>15</sup>. H&#225; rela&#231;&#227;o entre interna&#231;&#245;es, mortalidade por IC e epidemias de influenza, assim como as baixas temperaturas atmosf&#233;ricas. Pode-se inferir que os locais suscet&#237;veis &#224;s maiores amplitudes t&#233;rmicas e outras condi&#231;&#245;es atmosf&#233;ricas possam estar sob maior risco das infec&#231;&#245;es respirat&#243;rias<sup>9,23</sup>. A vacina&#231;&#227;o previne mortalidade em cardiopatas cr&#244;nicos nos meses do inverno<sup>20</sup>. </p>
    <p>A conscientiza&#231;&#227;o dos profissionais da sa&#250;de acerca da import&#226;ncia da vacina&#231;&#227;o contra influenza e pneumococo em todos os pacientes com IC, independente da faixa et&#225;ria, &#233; mandat&#243;ria. Afrodescendentes, n&#227;o diab&#233;ticos e pacientes sem pneumopatias constituem outros subgrupos que tamb&#233;m s&#227;o preteridos da vacina&#231;&#227;o<sup>16</sup>. Segundo os resultados deste estudo, a popula&#231;&#227;o rural ou em &#225;reas de dif&#237;cil acesso deve ter estrat&#233;gia diferenciada na vacina&#231;&#227;o. A taxa de vacina&#231;&#227;o contra influenza nos EUA est&#225; est&#225;vel e abaixo das metas tra&#231;adas. Pelos resultados ora encontrados, infere-se que nossas taxas s&#227;o ainda inferiores &#224;s norte-americanas. </p>
    <p>A facilita&#231;&#227;o ao acesso &#224; vacina, atrav&#233;s das diversas estrat&#233;gias de distribui&#231;&#227;o, campanhas, direcionamento para ambulat&#243;rios gerais e especializados, pode incrementar a efici&#234;ncia do processo<sup>14,24</sup>. A abordagem multiprofissional e sistematizada aos pacientes com IC, conforme praticado nas "<italic>Cl&#237;nicas de Insufici&#234;ncia Card&#237;aca</italic>", s&#227;o eficazes na redu&#231;&#227;o de interna&#231;&#245;es atrav&#233;s da otimiza&#231;&#227;o da terap&#234;utica farmacol&#243;gica e n&#227;o farmacol&#243;gica, incluindo a vacina&#231;&#227;o. Entretanto, as experi&#234;ncias de atendimento multiprofissional aos pacientes com IC ainda se restringem aos centros universit&#225;rios, em especial, aos grupos que oferecem transplante card&#237;aco. N&#227;o h&#225; pol&#237;ticas p&#250;blicas com programas voltados aos pacientes com IC atendidos na aten&#231;&#227;o prim&#225;ria, a exemplo daquelas oferecidas aos diab&#233;ticos e hipertensos.</p>
    <p>
      <bold>Conclus&#245;es</bold>
    </p>
    <p>A taxa de vacina&#231;&#227;o contra influenza e pneumococo em pacientes com IC &#233; muito baixa e ainda menor naqueles descompensados atendidos em servi&#231;o de emerg&#234;ncia.</p>
    <p>Faz-se necess&#225;ria a implementa&#231;&#227;o de medidas para incrementar a taxa de vacina&#231;&#227;o contra infec&#231;&#245;es respirat&#243;rias nos pacientes com IC e, desta forma, diminuir as descompensa&#231;&#245;es e as interna&#231;&#245;es.</p>
    <p>
      <bold>Agradecimentos</bold>
    </p>
    <p>A Secretaria Municipal de Sa&#250;de de Teres&#243;polis e a Funda&#231;&#227;o Carlos Chagas Filho de Amparo &#224; Pesquisa no Estado do Rio de Janeiro (FAPERJ).</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo foi parcialmente financiado pelo Centro Universit&#225;rio Serra dos &#211;rg&#227;os e FAPERJ.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="nt" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Wolney de Andrade Martins </p>
        <p> Hospital Universit&#225;rio Antonio Pedro - Servi&#231;o de Cardiologia </p>
        <p> Rua Marqu&#234;s do Paran&#225;, 303/6&#186; andar - Centro </p>
        <p> 24030-215 - Niter&#243;i, RJ - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="wolney@cardiol.br">wolney@cardiol.br</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 10/01/10; revisado recebido em 25/07/10; aceito em 09/08/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation. 2009;119(14):1977-2016.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults</article-title>
          <source>Circulation</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1977</fpage>
          <lpage>2016</lpage>
          <issue>14</issue>
          <volume>119</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jessup</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Casey</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Ganiats</surname>
              <given-names>TG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Bocchi EA, Marcondes-Braga FG, Ayub-Ferreira SM, Rohde LE, Oliveira WA, Almeida DR, et al. / Sociedade Brasileira de Cardiologia. III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica. Arq Bras Cardiol. 2009;92(6 supl.1):1-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sociedade Brasileira de Cardiologia: III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1</fpage>
          <lpage>71</lpage>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Marcondes-Braga</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Ayub-Ferreira</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Rohde</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Bratzler DW, Houck PM, Jiang H, Nsa W, Shook C, Moore L, et al. Failure to vaccinate medicare inpatients. Arch Intern Med. 2002;162(20):2349-56.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Failure to vaccinate medicare inpatients</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>2349</fpage>
          <lpage>56</lpage>
          <issue>20</issue>
          <volume>162</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bratzler</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Houck</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nsa</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Shook</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Nichol K, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348(14):1322-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1322</fpage>
          <lpage>32</lpage>
          <issue>14</issue>
          <volume>348</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nichol</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nordin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mullooly</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lask</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fillbrandt</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iwane</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29(19):2388-442.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>2388</fpage>
          <lpage>442</lpage>
          <issue>19</issue>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dickstein</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cohen-Solal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Filippatos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>McMurray</surname>
              <given-names>JJV</given-names>
            </name>
            <name>
              <surname>Ponikowski</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Poole-Wilson</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Bocchi EA, Vilas-Boas F, Perrone S, Caama&#241;o AG, Clausell N, Moreira MCV, et al. / Sociedade Brasileira de Cardiologia. I Diretriz Latino-Americana para avalia&#231;&#227;o e conduta na insufici&#234;ncia card&#237;aca descompensada. Arq Bras Cardiol. 2005;85(supl. 3):1-48.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sociedade Brasileira de Cardiologia: I Diretriz Latino-Americana para avalia&#231;&#227;o e conduta na insufici&#234;ncia card&#237;aca descompensada</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1</fpage>
          <lpage>48</lpage>
          <volume>85</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Vilas-Boas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Perrone</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Caama&#241;o</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Clausell</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>MCV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Minist&#233;rio da Sa&#250;de. Manual para os centros de refer&#234;ncia de imunobiol&#243;gicos especiais 2006. [Acesso em 2009 dez 30]. Dispon&#237;vel em <ext-link ext-link-type="uri" xlink:href="http://portal.saude.gov.br/portal/arquivos/pdf/">http://portal.saude.gov.br/portal/arquivos/pdf/</ext-link>.</mixed-citation>
        <element-citation publication-type="book">
          <source>Manual para os centros de refer&#234;ncia de imunobiol&#243;gicos especiais 2006</source>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Araujo DV, Tavares LR, Ver&#237;ssimo R, Ferraz MB, Mesquita ET. Custo da insufici&#234;ncia card&#237;aca no Sistema &#218;nico de Sa&#250;de. Arq Bras Cardiol. 2005;84(5):422-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Custo da insufici&#234;ncia card&#237;aca no Sistema &#218;nico de Sa&#250;de</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>422</fpage>
          <lpage>7</lpage>
          <issue>5</issue>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Araujo</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Tavares</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Ver&#237;ssimo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ferraz</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Sandoval C, Walter SD, Krueger P, Smieja M, Smith A, Yusuf S, et al. Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure. Epidemiol Infect. 2007;135(4):574-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure</article-title>
          <source>Epidemiol Infect</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>574</fpage>
          <lpage>82</lpage>
          <issue>4</issue>
          <volume>135</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sandoval</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Walter</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Krueger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Smieja</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association / American College of Cardiology. J Am Coll Cardiol. 2006;48(7):1498-502.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association / American College of Cardiology</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1498</fpage>
          <lpage>502</lpage>
          <issue>7</issue>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Davis</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Taubert</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Benin</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Mensah</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Baddour</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Sandoval C, Walter S, Krueger P, Loeb M. Comparing estimates of influenza-associated hospitalization and death among adults with congestive heart failure based on how influenza season is defined. BMC Public Health. 2008,8(59):1-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparing estimates of influenza-associated hospitalization and death among adults with congestive heart failure based on how influenza season is defined</article-title>
          <source>BMC Public Health</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <issue>59</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sandoval</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Walter</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Krueger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Loeb</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Doing A, Griffin D, Jacobson JA, Amber IJ, Gilbert E. B-cell function in chronic heart failure: antibody response to pneumococcal vaccine. J Card Fail. 2001;7(4):318-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>B-cell function in chronic heart failure: antibody response to pneumococcal vaccine</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>318</fpage>
          <lpage>21</lpage>
          <issue>4</issue>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Doing</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Amber</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Minist&#233;rio da Sa&#250;de. Secretaria Nacional de Vigil&#226;ncia em Sa&#250;de. Relat&#243;rio de situa&#231;&#227;o: Rio de Janeiro, 2006. [Acesso em 2010 jun 21]. Dispon&#237;vel em <ext-link ext-link-type="uri" xlink:href="http://bvsms.saude.gov.br/bvs/publicacoes/relatorio_snvs_rj_2ed.pdf">http://bvsms.saude.gov.br/bvs/publicacoes/relatorio_snvs_rj_2ed.pdf</ext-link>.</mixed-citation>
        <element-citation publication-type="book">
          <source>Relat&#243;rio de situa&#231;&#227;o: Rio de Janeiro, 2006</source>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Singleton J, Wortley P, Lu P. Influenza vaccination of persons with cardiovascular disease in the United States. Tex Heart Inst J. 2004;31(1):22-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Influenza vaccination of persons with cardiovascular disease in the United States</article-title>
          <source>Tex Heart Inst J</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>22</fpage>
          <lpage>7</lpage>
          <issue>1</issue>
          <volume>31</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Singleton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wortley</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Hak E, Buskens E, van Essen GA, Bakker DH, Grobbee DE, Tcaken MAJB, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the Prisma Study. Arch Intern Med. 2005;165(3):274-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the Prisma Study</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>274</fpage>
          <lpage>80</lpage>
          <issue>3</issue>
          <volume>165</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hak</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Buskens</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>van Essen</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Bakker</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Grobbee</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Tcaken</surname>
              <given-names>MAJB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Brittner V. Influenza vaccination in secondary prevention: an opportunity missed. J Cardiopulm Rehabil Prev. 2007;27(4):202-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Influenza vaccination in secondary prevention: an opportunity missed</article-title>
          <source>J Cardiopulm Rehabil Prev</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>202</fpage>
          <lpage>7</lpage>
          <issue>4</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brittner</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Jim&#233;nez-Garcia R, Hernandez-Barrera V, Garrido PC, del Pozo SVF, Miguel AG. Influenza vaccination among cardiovascular disease sufferers in Spain: related factors and trend, 1993-2003. Vaccine. 2006;24(23):5073-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Influenza vaccination among cardiovascular disease sufferers in Spain: related factors and trend, 1993-2003</article-title>
          <source>Vaccine</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>5073</fpage>
          <lpage>82</lpage>
          <issue>23</issue>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jim&#233;nez-Garcia</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hernandez-Barrera</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Garrido</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>del Pozo</surname>
              <given-names>SVF</given-names>
            </name>
            <name>
              <surname>Miguel</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Martins WA, Souza RT, Cabral IF, Furquim TA, Ribeiro MD, Nogueira LS, et al. Influenza and pneumococcal vaccination in heart failure patients: a neglected recommendation. J Card Fail. 2009;15(6):S83.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Influenza and pneumococcal vaccination in heart failure patients: a neglected recommendation</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>S83</fpage>
          <issue>6</issue>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Martins</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Cabral</surname>
              <given-names>IF</given-names>
            </name>
            <name>
              <surname>Furquim</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Nogueira</surname>
              <given-names>LS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Gurfinkel E, Mautner B. Secondary prevention of coronary artery disease. Flu vaccinations and new evidence of the role of infection in acute coronary syndromes. Rev Esp Cardiol. 2002;55(10):1009-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Secondary prevention of coronary artery disease: Flu vaccinations and new evidence of the role of infection in acute coronary syndromes</article-title>
          <source>Rev Esp Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1009</fpage>
          <lpage>12</lpage>
          <issue>10</issue>
          <volume>55</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gurfinkel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mautner</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. de Diego C, Vilo-C&#243;rcoles A, Ochoa O, Rodriguez T, Salsench E, Hospital I, et al. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J. 2009;30(2):209-16.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>209</fpage>
          <lpage>16</lpage>
          <issue>2</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>de Diego</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vilo-C&#243;rcoles</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ochoa</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Salsench</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hospital</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Fuente R, Gurfinkel E, Toledo D, Mautner B. Flu vaccination in patients with acute coronary syndromes: Treatment benefit in prespecified subgroups. Rev Esp Cardiol. 2003;56(10):949-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Flu vaccination in patients with acute coronary syndromes: Treatment benefit in prespecified subgroups</article-title>
          <source>Rev Esp Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>949</fpage>
          <lpage>54</lpage>
          <issue>10</issue>
          <volume>56</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fuente</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gurfinkel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Toledo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mautner</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Mansur AP, Favarato D, Ramires JAF. Vacina contra o v&#237;rus da Influenza e mortalidade por doen&#231;as cardiovasculares na cidade de S&#227;o Paulo. Arq Bras Cardiol. 2009;93(4):395-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vacina contra o v&#237;rus da Influenza e mortalidade por doen&#231;as cardiovasculares na cidade de S&#227;o Paulo</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>395</fpage>
          <lpage>9</lpage>
          <issue>4</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mansur</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Favarato</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ramires</surname>
              <given-names>JAF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Jorge JEL, Cagy M, Mesquita ET, Costa TLM, Moscavitch SD, Rosa MLG. Seasonal variation in hospitalizations due to heart failure in Niter&#243;i city, Southeastern Brazil. Rev Sa&#250;de P&#250;blica. 2009;43(3):555-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Seasonal variation in hospitalizations due to heart failure in Niter&#243;i city, Southeastern Brazil</article-title>
          <source>Rev Sa&#250;de P&#250;blica</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>555</fpage>
          <lpage>7</lpage>
          <issue>3</issue>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jorge</surname>
              <given-names>JEL</given-names>
            </name>
            <name>
              <surname>Cagy</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>TLM</given-names>
            </name>
            <name>
              <surname>Moscavitch</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Rosa</surname>
              <given-names>MLG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Gopal S, Davis M. Delivery of Influenza vaccine to non-elderly persons with cardiovascular disease, with varying national supply of vaccine. Hum Vaccin. 2005;1(6):217-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Delivery of Influenza vaccine to non-elderly persons with cardiovascular disease, with varying national supply of vaccine</article-title>
          <source>Hum Vaccin</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>217</fpage>
          <lpage>23</lpage>
          <issue>6</issue>
          <volume>1</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gopal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Influenza and pneumococcal vaccination in heart failure: a little applied recommendation</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Heart failure (HF) is associated with frequent decompensation and admissions to the emergency service. Influenza (INF) and Pneumococcal (pneumonia) vaccinations are recommended in the guidelines, however, respiratory infections are the third leading cause of hospitalization in heart failure. OBJECTIVE: To assess the frequency of vaccination against INF and PNM in patients with HF in government healthcare units. METHODS: An observational study carried out in Teres&#243;polis, a mountain region in Rio de Janeiro, employed three strategies: (I) study of requests for vaccine against INF and/or PNM in the Health Department of Teres&#243;polis between 2004 and 2006; (II) direct inquiry to 61 patients with heart failure treated in primary care about their vaccination status against INF and PNM; (III) direct inquiry about their vaccination status against INF and PNM to 81 patients with decompensated chronic heart failure treated in the only emergency service open to the public. RESULTS: In strategy I, INF and/or PNM vaccination was 15.3% of those with indications for cardiovascular and respiratory diseases. The median time between indication and vaccination was 32 days. In strategy II, the percentage of patients vaccinated against INF, aged &gt; 60, was 23.1% and 24.6% against PMN at all ages. In strategy III, the percentage of patients vaccinated against INF was 35.8% and against PNM was 2.5%. CONCLUSION: The rate of vaccination against INF and PNM in patients with HF is very low and even lower in those with decompensated HF treated in emergency services.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Vaccination</kwd>
        <kwd>influenza</kwd>
        <kwd>human</kwd>
        <kwd>pneumonia</kwd>
        <kwd>heart failure</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p><undefined id="tx-body2"/>Influenza and pneumococcal vaccination in heart failure - a little applied recommendation</p>
      <p>
        <bold>Wolney de Andrade Martins; Margarete Domingues Ribeiro; Lucia Brand&#227;o de Oliveira; Luciana da Silva Nogueira de Barros; Ana Cristina da Silva Moreira Jorge; Camila Mirante dos Santos; Daniella de Paiva Almeida; Isa&#237;as Fiuza Cabral; Renata Tavares de Souza; Thyago Ant&#244;nio Biagioni Furquim</bold>
      </p>
      <p> Cl&#237;nica de Insufici&#234;ncia Card&#237;aca (CLIC) do Hospital das Cl&#237;nicas de Teres&#243;polis Costantino Ottaviano (HCTCO) - Centro Universit&#225;rio Serra dos &#211;rg&#227;os (UNIFESO), Teres&#243;polis, RJ - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Heart failure (HF) is associated with frequent decompensation and admissions to the emergency service. Influenza (INF) and Pneumococcal (pneumonia) vaccinations are recommended in the guidelines, however, respiratory infections are the third leading cause of hospitalization in heart failure.</p>
      <p><bold>OBJECTIVE:</bold> To assess the frequency of vaccination against INF and PNM in patients with HF in government healthcare units.</p>
      <p><bold>METHODS:</bold> An observational study carried out in Teres&#243;polis, a mountain region in Rio de Janeiro, employed three strategies: (I) study of requests for vaccine against INF and/or PNM in the Health Department of Teres&#243;polis between 2004 and 2006; (II) direct inquiry to 61 patients with heart failure treated in primary care about their vaccination status against INF and PNM; (III) direct inquiry about their vaccination status against INF and PNM to 81 patients with decompensated chronic heart failure treated in the only emergency service open to the public.</p>
      <p><bold>RESULTS:</bold> In strategy I, INF and/or PNM vaccination was 15.3% of those with indications for cardiovascular and respiratory diseases. The median time between indication and vaccination was 32 days. In strategy II, the percentage of patients vaccinated against INF, aged &gt; 60, was 23.1% and 24.6% against PMN at all ages. In strategy III, the percentage of patients vaccinated against INF was 35.8% and against PNM was 2.5%.</p>
      <p><bold>CONCLUSION:</bold> The rate of vaccination against INF and PNM in patients with HF is very low and even lower in those with decompensated HF treated in emergency services.</p>
      <p><bold>Keywords:</bold> Vaccination; influenza, human; pneumonia; heart failure.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Heart failure (HF) is a progressive clinical syndrome characterized by heart muscle failure to pump enough blood to the organic systems. Increase in cardiovascular risk factors and greater longevity of the population contribute for the HF to have an epidemic form. HF is associated with frequent readmissions and each has additional weight in the worsening of the survival curve. The main factors that precipitate decompensation and hospitalization include failure to follow the treatment, acute myocardial ischemia, high blood pressure and respiratory infections such as pneumonia and viral diseases<sup>1-2</sup>.</p>
      <p>Pulmonary congestion is present in most patients with HF and predisposes them to respiratory infections. These include influenza due to high prevalence in the community, with direct and indirect action in mortality and hospitalization of patients more vulnerable to viral complications, especially the elderly. Influenza and pneumococcal vaccination has decreased overall and cardiovascular mortality in the elderly, and has reduced the risk of hospitalization for pneumonia or death from all causes<sup>3-4</sup>. Epidemiological evidence has encouraged vaccination programs in high-risk populations. The societies specializing in cardiology in North America<sup>1</sup>, Europe<sup>5</sup> and Latin America<sup>6</sup> included in their guidelines the recommendation of influenza and pneumococcal vaccination in chronic cardiac patients. In Brazil, both the Ministry of Health<sup>7</sup> and the Brazilian Society of Cardiology<sup>2</sup> (SBC) also recommend vaccinations against influenza and pneumonia in these patients.</p>
      <p>Considering the clinical and epidemiological importance of HF, the importance of vaccination as a prophylactic measure and the lack of data on the effectiveness of the recommendation of vaccination in Brazil, this study aimed to estimate the rate of influenza and pneumococcal vaccination in patients with HF under outpatient care and patients with decompensated heart failure, treated in government healthcare units of Teres&#243;polis, a mountainous region of Rio de Janeiro.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>The study was conducted in the city of Teres&#243;polis, mountainous region of the state, with annual average temperatures below the national average, and 150,268 inhabitants in 2007. Outpatient care controlled by the government is operated by the family health strategy (ESF) in 29.5%, and complemented by other basic care units (UBS) with total coverage of 35.3% of the population. The secondary units are linked with the primary care system through the reference and counterreference system. The ESF is jointly administered by the SUS (Brazilian Health System) and the <italic>Centro Universit&#225;rio Serra dos &#211;rg&#227;os </italic>(UNIFESO), an education institution with six undergraduate courses in health, with effective inclusion of professors and students from the said system. The largest tertiary unit is the medium-sized teaching hospital linked to SUS as the single urgency and emergency service open to the local public at the time of the study. </p>
      <p>The study was observational, cross-sectional and consisted of three strategies: </p>
      <p>
        <bold>Strategy I</bold>
      </p>
      <p>Study of all "<italic>Special Immunobiological Requests</italic>" in the Health Department (SMS) of Teres&#243;polis filed from January 2004 to December 2006, with special emphasis given to requests for influenza and/or pneumococcal vaccination with an indication for cardiovascular and respiratory diseases for adolescents and adults, considered those older than 12. It considered as clinical indication for HF all statements made in the request form listed below: "heart failure", "cardiomyopathy", "ischemic, alcoholic, hypertensive, rheumatic, valvular heart disease, peripartum or other specific etiology." In one case it was not possible to determine the indication. </p>
      <p>Vaccination against influenza and pneumococcus in special groups for clinical purposes happens by reference and scheduling in a single central unit. There is no vaccination against pneumococcus in ESF or UBS units or sub units or campaigns in this city. Vaccination against pneumococcus is exclusive to those with clinical indication, composed of several entities and situations. Therefore, there is no indication for vaccination based on age.</p>
      <p>
        <bold>Strategy II</bold>
      </p>
      <p>Direct Inquiry to 61 patients diagnosed with HF seen at ESF, UBS or secondary units on their situation on influenza vaccination in the year preceding the interview and against pneumococcus in the 5 years preceding the interview. Patients were admitted to the protocol in random order of arrival to the units with a mean age of 66.5 &#177; 11.8 years, with 52.0% female. Randomly, 8 units of ESF, one UBS and one secondary unit were covered in the sample. The sampling proportionality between urban (6) and units (3) on the population distribution was duly respected. For sample calculation, we worked with unadjusted prevalence of HF of 2.0%. The sample comprised 2.0% of the number expected of HF patients in the city.</p>
      <p>
        <bold>Strategy III</bold>
      </p>
      <p>Direct Inquiry to 81 patients diagnosed with chronic acute HF seen at emergency services on their situation on influenza vaccination in the year preceding the interview and against pneumococcus in the 5 years preceding the interview. All patients were decompensated and were included regardless of etiology, severity levels, causes of decompensation or other criteria. The order of admission to the protocol was randomized by the date of service, with direct collection of data, in the shifts covered by the researchers. Whenever patients failed to provide information on their clinical severity, we used data provided by their family or anyone accompanying them. We excluded patients with acute HF ("de novo") and those with acute coronary syndrome or myocarditis, because they would have had previous diagnosis and the opportunity to vaccinate. Data collection took place between April 2007 to November 2008. The patients had different outcomes, such as discharge for outpatient monitoring, hospitalization or death. The mean age was 63.6 &#177; 14.0 years, 52.0% were male. That was the only emergency service open to the public in the city at the time of data collection and the sample collected from decompensated patients represented 2.7% of the estimated overall prevalence of HF not adjusted in the city, for all functional classes.</p>
      <p>Data were collected after the qualification and training of interviewers in the pilot study. A structured questionnaire was used and later transferred to a spreadsheet. The results were presented as absolute values and percentages. A comparison of the distribution of proportions between groups was performed using the chi-square test. The level of significance adopted was 0.05. </p>
      <p>The study was approved by the Ethics Committee on Research of UNIFESO under number 060 and 061/2006, as well as approval from the Health Department of Teres&#243;polis. All patients in strategies II and III signed a consent form after receiving information. This project was supported by the Program for Undergraduate Scientific and Continuing Studies (UNIFESO-PICP) and <italic>Funda&#231;&#227;o Carlos Chagas Filho de Amparo &#224; Pesquisa of the State of Rio de Janeiro</italic> (FAPERJ).</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>
        <bold>Strategy I</bold>
      </p>
      <p>In the three-year period analyzed, there were 735 pneumococcal vaccinations in the city of Teresopolis, predominantly in the pediatric population with 418 (56.9%), followed by vaccination in patients aged <underline>&gt;</underline> 12 for all other clinical indications other than cardiovascular or respiratory diseases with 168 (22.9%). Finally, those with respiratory or cardiovascular indication aged <underline>&gt;</underline> 12 with 149 (20.3%). Over this period, there were 184 references to influenza and/or pneumococcal vaccination to the Central Unit, which were 131 doses against pneumococcus, 35 against influenza and 18 against both. The median time between the indication of the vaccine by the assistant physician and the date of vaccination was 32 days, ranging from 1 to 377 days. Other characteristics of individuals vaccinated against INF and/or PNM are shown in <xref ref-type="table" rid="tab01-body2">Table 1</xref>.</p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0240-00010-gt01-en.jpg"/></table-wrap>
      <p>Out of those vaccinated against INF and/or PNM in the central unit, 183 patients had indications analyzed and vaccination for clinical indication for HF occurred in 15.3% of those referred for respiratory or cardiovascular diseases. The main indication was "<italic>recurrent pneumonia</italic>" in patients with pulmonary disease (see <xref ref-type="table" rid="tab02-body2">Table 2</xref>).</p>
      <table-wrap id="tab02-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0240-00010-gt02-en.jpg"/></table-wrap>
      <p>
        <bold>Strategy II</bold>
      </p>
      <p>Out of the 61 patients evaluated at primary and secondary units, the percentage of HF patients vaccinated against influenza was 72.1% <italic>versus</italic> 24.6% who denied having received the vaccination, and 3.3% were unaware. When taken separately, in those younger than 60, we obtained 23.1% of individuals vaccinated against influenza in relation to all patients in this age group. With respect to pneumococcal vaccination, the percentage of patients who said they had taken the vaccine was 24.6% against 57.4% who denied it and 18.0% who were unaware.</p>
      <p>
        <bold>Strategy III</bold>
      </p>
      <p>Out of the 81 patients with decompensated HF treated in the emergency department, the percentage of patients vaccinated against influenza was 35.8% against 64.2% who denied having received it. The percentage of patients who reported having received pneumococcal vaccination within the past 5 years was 2.5%, while 62.9% denied having received such vaccination and 34.6% were unaware of it.</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>The incidence of HF in the USA is approximately 1,000 per 100,000 of the inhabitants after 65 years of age, of which 75.0% have hypertension as the probable cause<sup>1</sup>. The prevalence of HF increases linearly with age in both sexes and severity is greater at the extremes of the age group<sup>6</sup>. In Canada, it reaches 350,000, while in the U.S. approximately 5 million people have HF. In Sweden, it is estimated to reach 2.0% of the population<sup>8,9</sup>. In Brazil, the prevalence of HF is uncertain, however, it is on a rising trend due to increased survival of the general population and the increasing effectiveness of drugs to prolong life in patients with HF. For these reasons, HF represents the leading cause of hospitalization in the Brazilian Health System (SUS) in patients older than 65<sup>8</sup>.</p>
      <p>In the last two decades in Brazil, there was a gradual increase in hospital mortality rates for HF with reversal in recent years<sup>2</sup>. Hospitalizations contribute to the total annual cost of US$ 33.7 billion in the U.S. economy, and in Brazil, in 2002, the cost per patient hospitalized with HF was estimated at R$ 4,033.62<sup>1,8</sup>. Most of the financial cost of HF patients is due to frequent hospitalizations. The causal relationship between respiratory infection and clinical decompensation has been confirmed in several epidemiological studies. Vaccination against respiratory infections is cost effective as a public health measure. There was a higher number of hospitalizations for HF during periods of epidemic influenza<sup>4,9-11</sup>. </p>
      <p>Moreover, in nosocomial environment, patients with HF are at increased risk of lung infections, especially pneumonia<sup>12</sup>. There was no evaluation of cost-effectiveness of vaccination against influenza and pneumococcus in patients with HF in Brazil in the databases searched. However, it is plausible to infer that the vaccination strategy is very beneficial, mainly because other measures with greater financial cost, such as providing free medication for outpatients, have been studied with a favorable conclusion<sup>8</sup>.</p>
      <p>By analyzing the results of reference sheets for vaccination in the Health Department of Teres&#243;polis (SMS), we observed the irrelevant number of patients vaccinated against the magnitude of the prevalence of HF. The city of Teres&#243;polis had influenza vaccination coverage in the target population of seniors, 84.6% in 2004, 97.5% in 2005 and 117.2% in 2006<sup>13</sup>. </p>
      <p>Thus, one can consider that the low rate of vaccination in patients with HF found in this study did not derive from the absence of structural conditions that would enable vaccination against influenza and pneumococcus. The causes of low vaccination rate can be discussed according to: (1) little indication by health professionals; (2) difficulties of access to vaccination and complex vaccination processes; and (3) patient-dependent causes. </p>
      <p>The inclusion of vaccination in chronic cardiac patients is not incorporated into the practice of healthcare plans at basic and specialized healthcare units. Such assertion is based on the low rate of vaccination against influenza - vaccination available once a year in the very basic units - among those younger than 60, i.e., outside usual indication. In this study, we observed the prevalence of indications for pneumococcal vaccination by pediatricians. Among the indications for cardiovascular and respiratory diseases in adolescents and adults, there was a predominance of indication by pulmonologists compared with cardiologists and general practitioners who treat patients with heart failure.</p>
      <p>It is likely that the recommendation of vaccination by clinical indication is more incorporated into the clinical practice of pediatricians and pulmonologists than cardiologists and generalists. The causes of failure of assistant physicians to prescribe vaccinations were not the object of this study. However, it is likely to arise out of lack of information about indication of vaccinations to patients with heart failure and availability of such in government-controlled hospitals. </p>
      <p>There was a predominance of female patients and almost all urban households among those patients vaccinated against pneumococcus. These demographic characteristics suggest the probable influence of access to vaccination as a facilitator in the vaccination process. The median time between the indication of vaccination by the assistant physician and effective vaccination was also too long in this population. The fact that vaccination is not be applied on the same day it is requested results in obstacles such as transportation costs, difficulty in moving back to the hospital due to exertional dyspnea, availability of a caregiver and memorization of appointment dates. Elderly prejudice against vaccination, given the myth of potential adverse effects also contributes to low rate of vaccination. Despite the immunological abnormalities described in HF, such as increase of interleukins and tumor necrosis factor and hyper-lymphocyte reactivity, immune response to pneumococcal vaccination is effective, with production of antibodies against all serotypes tested<sup>12</sup>.</p>
      <p>The sample observed in primary care showed the average age expected for the syndrome in most clinical studies, with a slight predominance of females, which can be explained by greater access of women to primary care units<sup>8</sup>. The highest rate of influenza vaccination was certainly due to the Brazilian Campaign for Elderly Vaccination, as due to age segregation, most individuals vaccinated are older than 60, the cutoff point of routine indication for influenza vaccination. </p>
      <p>The availability of influenza vaccination each year at UBS and ESF are facilitators of vaccination. However, there is still a significant percentage of unvaccinated individuals, which is explained by unawareness of clinical indication and safety of vaccination in patients with heart failure among health professionals. </p>
      <p>Singleton et al<sup>14</sup> found that influenza vaccination coverage among patients with heart disease is associated with age, because they found 76.7% of vaccinated individuals older than 65, 49.2% between 50 and 64 years, and only 22.7% of individuals vaccinated aged between 18 and 49. Hak et al<sup>15</sup> and Bittner et al<sup>16</sup> also reported similar results when patients aged 65 or older with high-risk medical conditions had a higher rate of vaccination as compared to younger ones. A national study conducted in Spain confirmed the need for vaccination policies in those in younger age groups, since they are often set aside<sup>17</sup>. Bittner et al<sup>16</sup> cautioned that even with the recommendations of the <italic>World Health Organization</italic> and the <italic>Centers of Disease Control and Prevention</italic> (CDC) for influenza vaccination in patients with cardiovascular diseases, the coverage is less than expected, even in developed countries, since only 34.0% of North American patients with cardiovascular disease were vaccinated in 2005.</p>
      <p>In evaluating the pneumococcal vaccination coverage in primary care, data are even more alarming, and studies are more scarce. Bratzeler et al<sup>3</sup> reported that 54.1% of the entire U.S. population older than 65 have never received this vaccine. This study revealed that in ESF and UBS, the percentage of patients with HF who denied having received the pneumococcal vaccination was much lower than the influenza vaccination and literature data.</p>
      <p>The number of 81 patients with acute chronic HF was considered significant in relation to the forecast of the total number of patients with decomensated HF in the city and represented 2.7% of the total number of patients with HF not adjusted. Patients with decompensated HF can be divided into "recurrent" or acute HF - usually secondary to acute coronary syndromes or "acute decompensation of chronic HF." The latter was the object of this study, usually with cardiomyopathy of several causes. Those with recurrent HF had no opportunity of diagnosis and previous vaccination. As a rule, decompensated patients are those in stages C and D of the American College of Cardiologists/American Heart Association and previous class III and IV of the New York Heart Association, an even smaller subgroup. </p>
      <p>In the emergency department, there was predominance of male patients, which reflects the distribution of the HF syndrome. In 2007, HF was responsible for 2.6% of hospitalizations and 6.0% of deaths recorded by the Brazilian Health System, having consumed 3.0% of the funds intended to be employed in all admissions made by this system<sup>2</sup>. Data on hospitalization for HF in Brazil derive from diagnostic impressions raised at the time of admission and registered upon authorization for hospital admission (AIH). Such records are notoriously inaccurate due to heterogeneous nomenclatures of HF diagnoses, comorbidities and other diagnoses and contextual issues in the billing system of admissions. </p>
      <p>Vaccination rates among patients admitted with decompensated HF are lower than those of primary care. It is possible to infer that the event of decompensation in this group relates to the lower vaccination rate and lower overall adherence to therapy. Respiratory infections are among the most common causes of decompensation in several series. In our institution, decompensation due to respiratory infections are ranked second, after the transgression of salt intake and drug prescription, probably due to high temperature variation in the mountainous region of the state of Rio de Janeiro, especially in the Winter<sup>18</sup>. The time of hospital admission would be conducive to vaccination, however, Bratzer et al<sup>3</sup> demonstrated that this practice is not common.</p>
      <p>The benefits of vaccination against influenza and pneumococcus are not restricted to prevention of decompensation of HF due to respiratory infections. Vaccination has been related to other gains, such as the reduction of coronary events in both primary or secondary prevention, reduction of cerebrovascular accidents, decrease in hospitalizations and costs for other diseases, especially among the elderly<sup>15,19,20</sup>. The impact of influenza vaccination and reduced mortality from ischemic heart disease is speculated<sup>21,22</sup>. Vaccination brings benefits in the outcomes of mortality and morbidity for all age groups with clinical conditions of risk and is increases in most elderly patients<sup>15</sup>. There is a relationship between hospital admissions and death from heart failure and influenza epidemics, as well as low atmospheric temperatures. It can be inferred that those places susceptible to greater temperature ranges and weather conditions may be at greater risk of respiratory infections<sup>9,23</sup>. Vaccination prevents mortality in chronic cardiac patients in the Winter<sup>20</sup>. </p>
      <p>The awareness of health professionals about the importance of influenza and pneumococcal vaccination in all patients with HF, regardless of age, is mandatory. African descendants, non-diabetic patients, and those without lung diseases are also other subgroups that are set aside in vaccination<sup>16</sup>. According to the findings of this study, the rural population or those people living in inaccessible areas must be assigned a different strategy for vaccination. The rate of influenza vaccination in the U.S. is stable and below the targets set. In view of the results found by now, it appears that our rates are still lower than those in the U.S.</p>
      <p>Easier access to vaccination, through various distribution strategies, campaigns, referrals to general and specialist outpatient clinics, may increase the efficiency of the process<sup>14,24</sup>. Systematic and multidisciplinary approach to patients with HF, as practiced in the "Heart Failure Clinics" are effective in reducing hospitalizations by optimizing pharmacological and non pharmacological therapies, including vaccination. However, experiences of multidisciplinary care to patients with HF are still confined to universities, especially to groups that offer heart transplantation. There are no public policy programs directed to patients with HF in primary care, such as those offered to diabetic and hypertensive patients.</p>
      <p>
        <bold>Conclusions</bold>
      </p>
      <p>The rate of vaccination against INF and PNM in patients with HF is very low and even lower in those with decompensated HF treated in emergency services.</p>
      <p>It is necessary to implement measures to increase the rate of vaccination against respiratory infections in patients with heart failure and thereby reduce decompensation and hospitalizations.</p>
      <p>
        <bold>Acknowledgments</bold>
      </p>
      <p>The Health Department of the City of Teres&#243;polis and Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro (FAPERJ).</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was partially funded by <italic>Centro Universit&#225;rio Serra dos &#211;rg&#227;os</italic> and FAPERJ.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Vacunaci&#243;n contra influenza y neumococo en la insuficiencia card&#237;aca: una recomendaci&#243;n poco aplicada</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La insuficiencia card&#237;aca (IC) cursa con frecuentes descompensaciones y admisiones al servicio de emergencia. Vacunaci&#243;n contra Influenza (INF) y Neumococo (PNM) son recomendadas en las directrices, entre tanto, las infecciones respiratorias son la tercera causa de hospitalizaci&#243;n en la IC. OBJETIVO: Evaluar la frecuencia de la vacunaci&#243;n contra INF y PNM en pacientes con IC en la red p&#250;blica. M&#201;TODOS: En estudio observacional realizado en Teres&#243;polis, regi&#243;n serrana fluminense, fueron utilizadas tres estrategias: (I) estudio de las requisiciones para vacuna contra INF y/o PNM en la Secretar&#237;a Municipal de Salud, entre 2004 y 2006; (II) averiguaci&#243;n directa a 61 pacientes con IC atendidos en la atenci&#243;n b&#225;sica sobre su situaci&#243;n de vacuna contra INF y PNM; (III) averiguaci&#243;n directa sobre situaci&#243;n de vacuna contra INF y PNM a 81 pacientes con IC cr&#243;nica descompensada atendidos en la &#250;nica emergencia abierta a la red p&#250;blica. RESULTADOS: En la estrategia I, la vacunaci&#243;n contra INF y/o PNM fue de 15,3% de aquellos con indicaciones por enfermedades cardiovasculares y respiratorias. La mediana del tiempo entre la indicaci&#243;n y la vacunaci&#243;n fue de 32 d&#237;as. En la estrategia II, el porcentual de vacunados contra INF, con edad &gt; 60 a&#241;os, fue de 23,1%, y de 24,6% contra PMN en todas las edades. En la estrategia III, el porcentual de pacientes vacunados contra INF fue de 35,8% y contra PNM fue de 2,5%. CONCLUSI&#211;N: La tasa de vacunaci&#243;n contra INF y PNM en pacientes con IC es muy baja y aun menor en aquellos descompensados atendidos en servicio de emergencia.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Vacunaci&#243;n</kwd>
        <kwd>influenza humana</kwd>
        <kwd>neumon&#237;a</kwd>
        <kwd>insuficiencia card&#237;aca</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="enda-body3">
          <label>
            <bold>Vacunaci&#243;n contra influenza y neumococo en la insuficiencia card&#237;aca - una recomendaci&#243;n poco aplicada</bold>
          </label>
          <p>
            <bold>Wolney de Andrade Martins; Margarete Domingues Ribeiro; Lucia Brand&#227;o de Oliveira; Luciana da Silva Nogueira de Barros; Ana Cristina da Silva Moreira Jorge; Camila Mirante dos Santos; Daniella de Paiva Almeida; Isa&#237;as Fiuza Cabral; Renata Tavares de Souza; Thyago Ant&#244;nio Biagioni Furquim </bold>
          </p>
        </fn>
      </p>
      <p>Cl&#237;nica de Insufici&#234;ncia Card&#237;aca (CLIC) do Hospital das Cl&#237;nicas de Teres&#243;polis Costantino Ottaviano (HCTCO) - Centro Universit&#225;rio Serra dos &#211;rg&#227;os (UNIFESO), Teres&#243;polis, RJ - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> La insuficiencia card&#237;aca (IC) cursa con frecuentes descompensaciones y admisiones al servicio de emergencia. Vacunaci&#243;n contra Influenza (INF) y Neumococo (PNM) son recomendadas en las directrices, entre tanto, las infecciones respiratorias son la tercera causa de hospitalizaci&#243;n en la IC. </p>
      <p><bold>OBJETIVO:</bold> Evaluar la frecuencia de la vacunaci&#243;n contra INF y PNM en pacientes con IC en la red p&#250;blica. </p>
      <p><bold>M&#201;TODOS:</bold> En estudio observacional realizado en Teres&#243;polis, regi&#243;n serrana fluminense, fueron utilizadas tres estrategias: (I) estudio de las requisiciones para vacuna contra INF y/o PNM en la Secretar&#237;a Municipal de Salud, entre 2004 y 2006; (II) averiguaci&#243;n directa a 61 pacientes con IC atendidos en la atenci&#243;n b&#225;sica sobre su situaci&#243;n de vacuna contra INF y PNM; (III) averiguaci&#243;n directa sobre situaci&#243;n de vacuna contra INF y PNM a 81 pacientes con IC cr&#243;nica descompensada atendidos en la &#250;nica emergencia abierta a la red p&#250;blica. </p>
      <p><bold>RESULTADOS:</bold> En la estrategia I, la vacunaci&#243;n contra INF y/o PNM fue de 15,3% de aquellos con indicaciones por enfermedades cardiovasculares y respiratorias. La mediana del tiempo entre la indicaci&#243;n y la vacunaci&#243;n fue de 32 d&#237;as. En la estrategia II, el porcentual de vacunados contra INF, con edad &gt; 60 a&#241;os, fue de 23,1%, y de 24,6% contra PMN en todas las edades. En la estrategia III, el porcentual de pacientes vacunados contra INF fue de 35,8% y contra PNM fue de 2,5%. </p>
      <p><bold>CONCLUSI&#211;N: </bold>La tasa de vacunaci&#243;n contra INF y PNM en pacientes con IC es muy baja y aun menor en aquellos descompensados atendidos en servicio de emergencia. </p>
      <p><bold>Palabras clave:</bold> Vacunaci&#243;n, influenza humana, neumon&#237;a, insuficiencia card&#237;aca. </p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia card&#237;aca (IC) es un s&#237;ndrome cl&#237;nica progresivo caracterizada por la insuficiencia del m&#250;sculo card&#237;aco en bombear sangre suficiente para los sistemas org&#225;nicos. El crecimiento de los factores de riesgo cardiovascular y la mayor longevidad de la poblaci&#243;n contribuyen para que la IC tenga car&#225;cter epid&#233;mico. La IC cursa con reinternaciones frecuentes y cada una de ellas tiene peso adicional en el empeoramiento de la curva de sobrevida. Entre los principales factores que precipitan las descompensaciones y hospitalizaciones, se destacan la no adhesi&#243;n al tratamiento, la isquemia mioc&#225;rdica aguda, la presi&#243;n arterial elevada y las infecciones respiratorias, como neumon&#237;a y enfermedades virales<sup>1-2</sup>. </p>
      <p>La congesti&#243;n pulmonar est&#225; presente en gran parte de los pacientes con IC y predispone los mismos a las infecciones respiratorias. Entre ellas, se destaca la influenza por la alta prevalencia en la comunidad, con acci&#243;n directa y indirecta en la mortalidad y en la hospitalizaci&#243;n de los pacientes m&#225;s vulnerables a las complicaciones virales, en especial, la poblaci&#243;n a&#241;osa. La vacunaci&#243;n contra influenza y contra neumococo disminuy&#243; la mortalidad global y cardiovascular en a&#241;osos, adem&#225;s de haber reducido el riesgo de hospitalizaciones por neumon&#237;a o muerte de todas las causas<sup>3-4</sup>. Las evidencias epidemiol&#243;gicas motivaron los programas de vacunaci&#243;n en poblaciones bajo mayor riesgo. Las sociedades de especialistas en cardiolog&#237;a en la Am&#233;rica del Norte<sup>1</sup>, Europa<sup>5</sup> y Am&#233;rica Latina<sup>6</sup> incluyeron en sus directrices la recomendaci&#243;n de la vacunaci&#243;n contra influenza y la neumon&#237;a neumoc&#243;cica en card&#237;acos cr&#243;nicos. En el Brasil, tanto el Ministerio de Salud<sup>7</sup> como la Sociedade Brasileira de Cardiologia<sup>2</sup> (SBC) tambi&#233;n recomiendan las vacunas contra influenza y neumococo para esos pacientes. </p>
      <p>Considerada la importancia cl&#237;nica y epidemiol&#243;gica de la IC, la relevancia de la vacunaci&#243;n como medida profil&#225;ctica y la carencia de datos sobre la efectividad de la recomendaci&#243;n de la vacunaci&#243;n en el Brasil, el presente trabajo tuvo por objetivo estimar la tasa de vacunaci&#243;n contra influenza y neumococo en pacientes con IC bajo control ambulatorio y entre los descompensados, en la red p&#250;blica de Teres&#243;polis, regi&#243;n serrana fluminense. </p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>El estudio fue desarrollado en el municipio de Teres&#243;polis, regi&#243;n serrana fluminense, con temperaturas medias anuales abajo de la media nacional y con 150.268 habitantes en el a&#241;o de 2007. La atenci&#243;n ambulatoria en la red p&#250;blica es operada por la estrategia de salud de la familia (ESF) en 29,5% y complementada por las dem&#225;s unidades b&#225;sicas (UBS) con total de cobertura de 35,3% de la poblaci&#243;n. Las unidades secundarias se articulan con la atenci&#243;n b&#225;sica por el sistema de referencia y contrarreferencia. LA ESF es administrada en cogesti&#243;n entre el SUS y el Centro Universitario Serra dos &#211;rg&#227;os (UNIFESO), instituci&#243;n de ense&#241;anza con 6 cursos de grado en la &#225;rea de salud, con efectiva inserci&#243;n de docentes y estudiantes en la referida red. La mayor unidad terciaria es el hospital de ense&#241;anza, de medio porte, con convenio con el SUS, como &#250;nico servicio de urgencia y emergencia abierto a la red p&#250;blica de la regi&#243;n en la &#233;poca del estudio. </p>
      <p>El estudio fue observacional, transversal y consisti&#243; en tres estrategias: </p>
      <p>
        <bold>Estrategia I</bold>
      </p>
      <p>Estudio de todas las "<italic>Requisiciones de Imunobiol&#243;gicos Especiales</italic>" en la Secretar&#237;a Municipal de Salud (SMS) de Teres&#243;polis, protocoladas en el per&#237;odo entre ene/2004-dic/2006, con especial enfoque en las requisiciones de vacunaci&#243;n contra influenza y/o neumococo con indicaci&#243;n por enfermedades cardiovasculares y respiratorias para adolescentes y adultos, considerados como aquellos mayores de 12 a&#241;os de edad. Se consider&#243; indicaci&#243;n cl&#237;nica por IC todas las indicaciones hechas en la ficha de requisici&#243;n listadas a seguir: "insuficiencia card&#237;aca", "cardiomiopat&#237;a", "miocardiopatia", "cardiopat&#237;as isqu&#233;mica, alcoh&#243;lica, hipertensiva, reum&#225;tica, valvular, periparto u otra etiolog&#237;a espec&#237;fica". En un &#250;nico caso no se consigui&#243; determinar la indicaci&#243;n. </p>
      <p>La vacunaci&#243;n contra influenza y neumococo en grupos especiales, por indicaci&#243;n cl&#237;nica, acontece a trav&#233;s de referencia y listado en &#250;nica unidad central. No hay vacunaci&#243;n contra neumococo en unidades de ESF o UBS ni en unidades secundarias o campa&#241;as en ese municipio. La vacunaci&#243;n contra neumococo es exclusiva de los grupos con indicaci&#243;n cl&#237;nica, compuesto de varias entidades y situaciones. Por lo tanto, no hay indicaci&#243;n de vacunaci&#243;n basada en franja et&#225;rea. </p>
      <p>
        <bold>Estrategia II</bold>
      </p>
      <p>Averiguaci&#243;n directo a 61 pacientes con diagn&#243;stico atribuido de IC, atendidos en ESF, UBS o unidades secundarias sobre su situaci&#243;n de vacuna contra influenza en el a&#241;o anterior a la entrevista y contra neumococo en los 5 a&#241;os anteriores a la entrevista. Los pacientes fueron admitidos al protocolo por orden aleatoria de llegada a las unidades y presentaron media de edad de 66,5 &#177; 11,8 a&#241;os, con 52,0% del sexo femenino. De modo aleatorio, 8 unidades de ESF, una UBS y una unidad secundaria fueron cubiertas en el muestreo. Se respet&#243; la proporcionalidad de muestreo entre unidades urbanas (seis) y rurales (tres) referente a la distribuci&#243;n de la poblaci&#243;n. Para fines de c&#225;lculo de la muestra, se trabaj&#243; con la prevalencia no ajustada de IC de 2,0%. La muestra estudiada represent&#243; 2,0% del total esperado de pacientes con IC en el municipio. </p>
      <p>
        <bold>Estrategia III</bold>
      </p>
      <p>Averiguaci&#243;n directa a 81 pacientes con diagn&#243;stico atribuido de IC cr&#243;nica agudizada atendidos en el servicio de emergencia sobre su situaci&#243;n de vacuna contra influenza, en el a&#241;o anterior a la entrevista, y contra neumococo, en los 5 a&#241;os anteriores a la entrevista. Todos los pacientes se encontraban descompensados y fueron incluidos independientemente de las etiolog&#237;as, niveles de gravedad, causas de descompensaci&#243;n o otros criterios. La orden de admisi&#243;n al protocolo fue aleatoria por la fecha de la atenci&#243;n, con colecta directa de datos, en las guardias cubiertas por los investigadores. En la imposibilidad de que el paciente provea informaci&#243;n por la gravedad de su cuadro cl&#237;nico, se utilizaron datos provistos por el familiar o acompa&#241;ante. Fueron excluidos los pacientes con IC aguda ("de nuevo"), como aquellos con s&#237;ndromes coronarios agudos o miocarditis, pues no habr&#237;an tenido el diagn&#243;stico y la oportunidad previos para vacunaci&#243;n. La colecta de los datos se hizo entre abr/2007-nov/2008. Los pacientes tuvieron desenlaces variados, como alta para control ambulatorio, internaci&#243;n u &#243;bito. La media de edad del grupo fue de 63,6 &#177; 14,0 a&#241;os, siendo 52,0% del sexo masculino. Ese era el &#250;nico servicio de emergencia abierto a la red p&#250;blica en el municipio en la &#233;poca de la colecta de los datos y la muestra colectada de pacientes descompensados represent&#243; 2,7% de la estimativa de prevalencia general de IC no ajustada en el municipio, para todas las clases funcionales. </p>
      <p>Los datos fueron colectados despu&#233;s de capacitaci&#243;n de los entrevistadores y entrenamiento en estudio-piloto. Cuestionario estructurado fue utilizado y, posteriormente, transferido para planilla electr&#243;nica. Los resultados fueron presentados en valores absolutos y porcentuales. La comparaci&#243;n de la distribuci&#243;n de las proporciones entre los grupos fue hecha a trav&#233;s del test chi-cuadrado. El nivel de significaci&#243;n adoptado fue de 5,0%. </p>
      <p>El estudio tuvo aprobaci&#243;n en la Comisi&#243;n de &#201;tica en Investigaci&#243;n del UNIFESO, bajo el n&#250;mero 060 y 061/2006, as&#237; como la aprobaci&#243;n en la Secretar&#237;a Municipal de Salud de Teres&#243;polis. Todos los pacientes de las estrategias II y III firmaron t&#233;rmino de consentimiento despu&#233;s de aclaraci&#243;n. Este proyecto tuvo apoyo del Programa de Iniciaci&#243;n Cient&#237;fica, Investigaci&#243;n y Extensi&#243;n (PICPE-UNIFESO) y de la Fundaci&#243;n Carlos Chagas Filho de Amparo a la Investigaci&#243;n del Estado del Rio de Janeiro (FAPERJ). </p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>
        <bold>Estrategia I</bold>
      </p>
      <p>En el trienio analizado, hubo un total de 735 vacunaciones contra neumococo en todo el municipio de Teres&#243;polis, con predominio de la poblaci&#243;n pedi&#225;trica con 418 (56,9%), seguida de las vacunaciones en los pacientes con edad <sup>3</sup> 12 a&#241;os por todas las dem&#225;s indicaciones cl&#237;nicas que no fueran cardiovascular o respiratoria con 168 (22,9%). Por &#250;ltimo, aquellos por indicaci&#243;n cardiovascular o respiratoria con edad <sup>3</sup> 12 a&#241;os con 149 (20,3%). En el per&#237;odo analizado, hubo 184 referencias de vacunaci&#243;n contra influenza y/o neumococo a la Unidad Central, de las cuales fueron 131 dosis contra neumococo, 35 contra influenza y 18 contra ambas. La mediana del tiempo entre la indicaci&#243;n de la vacuna por el m&#233;dico asistente y la fecha de la vacunaci&#243;n fue de 32 d&#237;as, con intervalo de 1 a 377 d&#237;as. Dem&#225;s caracter&#237;sticas de los vacunados contra INF y/o PNM se encuentran dispuestas en la <xref ref-type="table" rid="tab1-body3">Tabla 1</xref>. </p>
      <table-wrap id="tab1-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0240-00010-gt01-es.jpg"/></table-wrap>
      <p>De los vacunados contra INF y/o PNM en la unidad central, 183 pacientes tuvieron las indicaciones analizadas y la vacunaci&#243;n por indicaci&#243;n cl&#237;nica de IC sucedi&#243; en 15,3% de los referenciados por enfermedades cardiovasculares o respiratorias. La principal indicaci&#243;n fue "<italic>neumon&#237;as de repetici&#243;n</italic>" en pacientes neum&#243;patas (ver <xref ref-type="table" rid="tab2-body3">Tabla 2</xref>). </p>
      <table-wrap id="tab2-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0240-00010-gt02-es.jpg"/></table-wrap>
      <p>
        <bold>Estrategia II</bold>
      </p>
      <p>De los 61 pacientes evaluados en las unidades primarias y secundarias, el porcentual de pacientes con IC vacunados contra influenza fue de 72,1% contra 24,6% que negaron haber recibido la misma, y aun 3,3% que desconoc&#237;an. Cuando fueron tomados en separado aquellos con edad menor que 60 a&#241;os, se obtuvo 23,1% de vacunados contra influenza en relaci&#243;n al total de pacientes en esta franja et&#225;rea. Con relaci&#243;n a la vacunaci&#243;n contra neumococo, el porcentual de pacientes que dijeron haber tomado la vacuna fue de 24,6%, contra 57,4% que lo negaron y 18,0% que lo desconoc&#237;an. </p>
      <p>
        <bold>Estrategia III</bold>
      </p>
      <p>De los 81 pacientes con IC descompensada atendidos en el servicio de emergencia, el porcentual de pacientes vacunados contra influenza fue de 35,8%, contra 64,2% que negaron haber recibido la misma. El porcentual de pacientes que afirmaron haber recibido la vacuna neumoc&#243;cica, en los &#250;ltimos 5 a&#241;os, fue de 2,5%, mientras que 62,9% negaron haber recibido la misma y 34,6% desconoc&#237;an la vacuna. </p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La incidencia de IC en los EUA es de aproximadamente 1.000 por 100.000 habitantes despu&#233;s de los 65 a&#241;os de edad, de los cuales 75,0% de los casos han la hipertensi&#243;n arterial sist&#233;mica como la probable etiolog&#237;a<sup>1</sup>. La prevalencia de IC aumenta linealmente con la edad en ambos sexos y la gravedad es mayor en los extremos de franja et&#225;rea<sup>6</sup>. En Canad&#225;, llega a alcanzar 350.000, mientras que en los EUA aproximadamente 5 millones de personas tienen IC. En Suecia, la estimativa es de que alcance 2,0% de la poblaci&#243;n<sup>8,9</sup>. En el Brasil, la prevalencia de IC es incierta, sin embargo, est&#225; en ascensi&#243;n debido a la mayor sobrevida de la poblaci&#243;n en general y a la mayor efectividad de los medicamentos para prolongaci&#243;n de la vida de los pacientes con IC. Por estas razones, la IC representa la principal causa de internaci&#243;n en el Sistema &#218;nico de Salud (SUS) en los pacientes encima de 65 a&#241;os de edad<sup>8</sup>. </p>
      <p>En las &#250;ltimas dos d&#233;cadas, en el Brasil, ocurri&#243; aumento progresivo de las tasas de mortalidad hospitalaria por IC con reversi&#243;n en los &#250;ltimos a&#241;os<sup>2</sup>. Las hospitalizaciones contribuyen para el costo total anual de 33,7 mil millones de d&#243;lares en la econom&#237;a americana, y en el Brasil, en el a&#241;o de 2002, el costo por paciente internado con IC fue estimado en R$ 4.033,62<sup>1,8</sup>. La mayor parte del costo financiero de los pacientes con IC se debe a las internaciones frecuentes. La relaci&#243;n causal entre infecci&#243;n respiratoria y descompensaci&#243;n cl&#237;nica ha sido comprobada en diversos estudios epidemiol&#243;gicos. La vacunaci&#243;n contra infecciones respiratorias tiene eficacia en la relaci&#243;n costo-beneficio como medida de salud p&#250;blica. Se observ&#243; mayor n&#250;mero de admisiones hospitalarias por IC durante per&#237;odos de epidemia de influenza<sup>4,9-11</sup>. </p>
      <p>Adem&#225;s de eso, en ambiente hospitalario, los pacientes con IC tienen riesgo aumentado de infecciones pulmonares, en especial neumon&#237;a<sup>12</sup>. No hubo evaluaci&#243;n de costo-efectividad de la vacunaci&#243;n contra influenza y neumococo en pacientes con IC en el Brasil en las bases consultadas. Entre tanto, es plausible inferir que la estrategia de vacunaci&#243;n sea muy favorable, hasta porque otras medidas con mayor costo financiero, como la provisi&#243;n de medicaci&#243;n gratuita a los pacientes ambulatorios, ya fueron estudiadas con conclusi&#243;n favorable<sup>8</sup>. </p>
      <p>Al analizar los resultados de las fichas de referencia para vacunaci&#243;n en la Secretar&#237;a Municipal de Salud (SMS), se observ&#243; el irrelevante n&#250;mero de vacunados frente a la magnitud de la prevalencia de la IC. El municipio de Teres&#243;polis tuvo cobertura de vacuna para influenza, en la poblaci&#243;n-blanco de a&#241;osos, de 84,6% en 2004, 97,5% en 2005 y 117,2% en 2006<sup>13</sup>. </p>
      <p>De este modo, se puede considerar que la baja tasa de vacunaci&#243;n en los pacientes con IC encontrada en este trabajo no fue consecuencia de la inexistencia de condiciones estructurales que viabilizasen la vacunaci&#243;n contra influenza y neumococo. Las causas de la baja tasa de vacunaci&#243;n pueden ser discutidas sobre tres ejes: (1) la poca indicaci&#243;n por el profesional de la salud; (2) las dificultades de acceso a la vacuna y la complejidad del proceso de vacunaci&#243;n; y (3) las causas dependientes del paciente. </p>
      <p>La inclusi&#243;n de la vacunaci&#243;n en card&#237;acos cr&#243;nicos no est&#225; incorporada a la pr&#225;ctica de los planos de cuidados de las unidades de la atenci&#243;n b&#225;sica y especializada. Tal afirmaci&#243;n es fundamentada en la baja tasa de vacunaci&#243;n contra influenza - vacuna disponible una vez al a&#241;o en las propias unidades b&#225;sicas - entre aquellos con edad menor de 60 a&#241;os, o sea, fuera de la indicaci&#243;n habitual. En este trabajo, se observ&#243; el predominio de indicaciones para vacunaci&#243;n contra neumococo por parte de los pediatras. Entre las indicaciones por enfermedades cardiovasculares y respiratorias en adolescentes y adultos, hubo predominio de la indicaci&#243;n por los neumon&#243;logos en relaci&#243;n a los cardi&#243;logos y generalistas que atienden pacientes con IC. </p>
      <p>Es probable que la recomendaci&#243;n de vacunaci&#243;n por indicaci&#243;n cl&#237;nica est&#233; m&#225;s incorporada a la pr&#225;ctica cl&#237;nica de los pediatras y neumon&#243;logos que de los cardi&#243;logos y generalistas. Las causas de la no prescripci&#243;n de las vacunas por los m&#233;dicos asistentes no fueron objeto de este trabajo, entre tanto, es posible que surjan de la falta de informaci&#243;n acerca de la indicaci&#243;n de las vacunas a los pacientes con IC y de la disponibilidad de las mismas en la red p&#250;blica. </p>
      <p>Hubo predominio de pacientes femeninos y casi totalidad de residencia urbana entre los vacunados contra neumococo. Tales caracter&#237;sticas demogr&#225;ficas se&#241;alan hacia la probable influencia del acceso a la vacuna como facilitador del proceso de vacunaci&#243;n. El tiempo mediano entre la indicaci&#243;n de la vacuna por el m&#233;dico asistente y la realizaci&#243;n de la vacunaci&#243;n tambi&#233;n fue demasiado largo en esta casu&#237;stica. El hecho de que la vacuna no sea aplicada el mismo d&#237;a en que es solicitada resulta en obst&#225;culos, como costo de transporte, limitaci&#243;n de desplazamiento por la disnea de esfuerzo, disponibilidad de acompa&#241;ante y memorizaci&#243;n de las fechas. El preconcepto de los a&#241;osos contra la vacunaci&#243;n, atribuido al mito de los posibles efectos adversos, tambi&#233;n corrobora la baja adherencia. A pesar de las alteraciones inmunol&#243;gicas descriptas en la IC, como aumento de las interleucinas y del factor de necrosis tumoral y la hiperreactividad linfocitaria, la respuesta inmunol&#243;gica a la vacunaci&#243;n neumoc&#243;cica es eficaz, con producci&#243;n de anticuerpos contra todos los serotipos testeados<sup>12</sup>. </p>
      <p>La muestra observada en la atenci&#243;n primaria present&#243; la media de edad esperada para el s&#237;ndrome en la mayor&#237;a de los estudios cl&#237;nicos, con discreto predominio del sexo femenino, lo que puede ser explicado por el mayor acceso de las mujeres a las unidades de atenci&#243;n b&#225;sica<sup>8</sup>. La mayor tasa de vacunaci&#243;n contra influenza se debi&#243;, seguramente, a la <italic>Campa&#241;a Nacional de Vacunaci&#243;n del A&#241;oso</italic>, puesto que, al separar por franjas et&#225;reas, se ve el predominio de los vacunados entre los mayores de 60 a&#241;os, punto de corte de la indicaci&#243;n rutinaria de la vacuna contra influenza. </p>
      <p>La disponibilidad de la vacuna contra influenza anualmente en las UBS y ESF son facilitadores de la vacunaci&#243;n. Entre tanto, aun hay significativo porcentual de no vacunados, lo que se explica por la falta de conocimiento de la indicaci&#243;n cl&#237;nica y de la seguridad de la vacuna en los pacientes con IC entre los profesionales de la salud. </p>
      <p>Singleton et al. <sup>14</sup> observaron que la cobertura de vacuna de influenza entre pacientes con enfermedad card&#237;aca est&#225; directamente asociada a la edad, pues encontraron 76,7% de individuos vacunados encima de los 65 a&#241;os, 49,2% entre 50 y 64 a&#241;os y, apenas, 22,7% vacunados con edad entre 18 y 49 a&#241;os. Hak et al. <sup>15</sup> y Bittner et al. <sup>16</sup> tambi&#233;n relataron resultados semejantes cuando pacientes con 65 a&#241;os o m&#225;s, con condiciones cl&#237;nicas de alto riesgo, tuvieron una mayor tasa de vacunaci&#243;n en relaci&#243;n a los de menor franja et&#225;rea. En estudio nacional realizado en Espa&#241;a, se corrobor&#243; la necesidad de pol&#237;ticas de vacunaci&#243;n en aquellos en franjas et&#225;reas menores, puesto que frecuentemente son postergados<sup>17</sup>. Bittner et al. <sup>16</sup> alertaron que aun con las recomendaciones de la Organizaci&#243;n Mundial de la Salud y del <italic>Centers of Disease Control and Prevention (CDC) </italic>para vacunaci&#243;n contra influenza en pacientes con enfermedades cardiovasculares, la cobertura se encuentra mas ac&#225; de lo esperado, aun en los pa&#237;ses desarrollados, una vez que apenas 34,0% de los pacientes norteamericanos con enfermedad cardiovascular fueron vacunados en 2005. </p>
      <p>Al evaluar la cobertura de vacuna contra neumococo en la atenci&#243;n b&#225;sica, los datos se vuelven aun m&#225;s alarmantes y los estudios m&#225;s escasos. Bratzeler et al. <sup>3</sup> afirmaron que 54,1% de toda la poblaci&#243;n norteamericana encima de 65 a&#241;os nunca recibieron esa vacuna. En el presente estudio, se observ&#243; que, en las ESF y UBS, el porcentual de pacientes con IC que negaron haber recibido la vacuna neumoc&#243;cica fue muy inferior a la vacuna contra influenza y a los datos de la literatura. </p>
      <p>El n&#250;mero presentado de 81 pacientes con IC cr&#243;nica agudizada fue considerado significativo en relaci&#243;n a la previsi&#243;n del n&#250;mero total de pacientes con IC descompensada en el municipio y represent&#243; 2,7% del n&#250;mero total de pacientes con IC no ajustado. Los pacientes con IC descompensada pueden ser divididos en IC "<italic>de nuevo" </italic>o<italic> aguda</italic> - generalmente secundarios a s&#237;ndromes coronarios agudos o "cr&#243;nico agudizado". Ese &#250;ltimo fue objeto del presente estudio, generalmente portador de cardiomiopat&#237;a de las diversas etiolog&#237;as. Aquellos con IC <italic>de nuevo</italic> no tuvieron oportunidades del diagn&#243;stico y de la vacunaci&#243;n previa. Los pacientes descompensados constituyen, en regla general, aquellos en los niveles C y D del <italic>American College of Cardiologists/American Heart Association </italic>y clase funcional previa III y IV de la <italic>New York Heart Association</italic>, o sea, subgrupo aun m&#225;s restringido. </p>
      <p>En el Servicio de Emergencia, hubo predominio de pacientes masculinos, lo que refleja la distribuci&#243;n del s&#237;ndrome de IC. En 2007, la IC fue responsable por 2,6% de las hospitalizaciones y 6,0% de los &#243;bitos registrados por el SUS en el Brasil, habiendo consumido 3,0% de los recursos utilizados para atender todas las internaciones realizadas por el sistema<sup>2</sup>. Los datos sobre internaci&#243;n por IC disponibles en el Brasil surgen de las impresiones diagn&#243;sticas levantadas a la &#233;poca de la internaci&#243;n y registradas en la autorizaci&#243;n para internaci&#243;n hospitalaria (AIH). Ese registro es sabidamente poco preciso por la heterogeneidad de las nomenclaturas de los diagn&#243;sticos habituales de la IC, comorbilidades y otros diagn&#243;sticos presentes y preguntas conyunturales del sistema de facturaci&#243;n de las internaciones. </p>
      <p>Las tasas de vacunaci&#243;n entre los pacientes admitidos descompensados son menores que aquellos de la atenci&#243;n b&#225;sica. Es posible inferir que el evento de la descompensaci&#243;n en ese grupo se relacione con la menor tasa de vacunaci&#243;n y en la menor adherencia general a la terap&#233;utica. Las infecciones respiratorias est&#225;n entre las causas m&#225;s comunes de descompensaci&#243;n en diversas series. En nuestra instituci&#243;n, las descompensaciones por infecciones respiratorias tienen el segundo lugar, despu&#233;s de la trasgresi&#243;n de la restricci&#243;n hidrosalina y medicamentosa, probablemente por la mayor amplitud t&#233;rmica en la regi&#243;n serrana fluminense, especialmente en los meses de invierno<sup>18</sup>. El momento de la internaci&#243;n hospitalaria ser&#237;a propicio para la vacunaci&#243;n, entre tanto, Bratzer et al. <sup>3</sup> demostraron que tal pr&#225;ctica no es com&#250;n. </p>
      <p>Los beneficios de la vacunaci&#243;n contra influenza y neumococo no se restringen a la prevenci&#243;n de la descompensaci&#243;n de la IC por infecciones respiratorias. La vacunaci&#243;n han sido relacionada a otras mejoras, tales como la disminuci&#243;n de eventos coronarios, tanto en la prevenci&#243;n primaria como en la secundaria; reducci&#243;n de los accidentes cerebrovasculares; disminuci&#243;n en las internaciones y costos por otras enfermedades, principalmente entre los a&#241;osos<sup>15,19,20</sup>. Se especula el impacto entre la vacunaci&#243;n contra influenza y la reducci&#243;n de mortalidad por enfermedad isqu&#233;mica del coraz&#243;n<sup>11,22</sup>. La vacunaci&#243;n trae beneficios en los desenlaces de mortalidad y morbilidad para todas las franjas et&#225;reas con condiciones cl&#237;nicas de riesgo y se acent&#250;a en los m&#225;s a&#241;osos<sup>15</sup>. Hay relaci&#243;n entre internaciones, mortalidad por IC y epidemias de influenza, as&#237; como las bajas temperaturas atmosf&#233;ricas. Se puede inferir que los lugares susceptibles a las mayores amplitudes t&#233;rmicas y otras condiciones atmosf&#233;ricas puedan estar bajo mayor riesgo de las infecciones respiratorias<sup>9,23</sup>. La vacunaci&#243;n previene mortalidad en card&#237;acos cr&#243;nicos en los meses de invierno<sup>20</sup>. </p>
      <p>La concientizaci&#243;n de los profesionales de la salud acerca de la importancia de la vacunaci&#243;n contra influenza y neumococo en todos los pacientes con IC, independiente de la franja et&#225;rea, es obligatoria. Afrodescendientes, no diab&#233;ticos y pacientes sin neumopat&#237;as constituyen otros subgrupos que tambi&#233;n son postergados en la vacunaci&#243;n<sup>16</sup>. Seg&#250;n los resultados de este estudio, la poblaci&#243;n rural o en &#225;reas de dif&#237;cil acceso debe tener estrategia diferenciada en la vacunaci&#243;n. La tasa de vacunaci&#243;n contra influenza en los EUA est&#225; estable y abajo de las metas trazadas. Por los resultados encontrados, se infiere que nuestras tasas son aun inferiores a las norteamericanas. </p>
      <p>La facilitaci&#243;n del acceso a la vacuna, a trav&#233;s de las diversas estrategias de distribuci&#243;n, campa&#241;as, orientaci&#243;n hacia ambulatorios generales y especializados, puede incrementar la eficiencia del proceso<sup>14,24</sup>. El abordaje multiprofesional y sistematizado a los pacientes con IC, seg&#250;n practicado en las "<italic>Cl&#237;nicas de Insuficiencia Card&#237;aca</italic>", son eficaces en la reducci&#243;n de internaciones a trav&#233;s de la optimizaci&#243;n de la terap&#233;utica farmacol&#243;gica y no farmacol&#243;gica, incluyendo la vacunaci&#243;n. Entre tanto, las experiencias de atenci&#243;n multiprofesional a los pacientes con IC aun se restringen a los centros universitarios, en especial, a los grupos que ofrecen transplante card&#237;aco. No hay pol&#237;ticas p&#250;blicas con programas volcados a los pacientes con IC atendidos en la atenci&#243;n primaria, a ejemplo de aquellas ofrecidas a los diab&#233;ticos e hipertensos. </p>
      <p>
        <bold>Conclusiones</bold>
      </p>
      <p>La tasa de vacunaci&#243;n contra influenza y neumococo en pacientes con IC es muy baja y aun menor en aquellos descompensados atendidos en servicio de emergencia. </p>
      <p>Se hace necesaria la implementaci&#243;n de medidas para incrementar la tasa de vacunaci&#243;n contra infecciones respiratorias en los pacientes con IC y, de esta forma, disminuir las descompensaciones y las internaciones. </p>
      <p>
        <bold>Agradecimientos</bold>
      </p>
      <p>La Secretar&#237;a Municipal de Salud de Teres&#243;polis y la <italic>Fundaci&#243;n Carlos Chagas Filho de Amparo a la Investigaci&#243;n en el Estado de Rio de Janeiro</italic> (FAPERJ). </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes. </p>
      <p>
        <bold>Fuentes de Financiamiento</bold>
      </p>
      <p>El presente estudio fue parcialmente financiado por el <italic>Centro Universitario Serra dos &#211;rg&#227;os</italic> y FAPERJ. </p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado. </p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
